<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">


<meta name="wpd_version" content="0.2">
<meta name="wpd_baseurl" content="http://www.nejm.org.libgate.library.nuigalway.ie/doi/full/10.1056/NEJMra025195">
<meta name="wpd_url" content="http://www.nejm.org.libgate.library.nuigalway.ie/doi/full/10.1056/NEJMra025195">
<meta name="wpd_date" content="2013-04-28T16:06Z">
<script src="auth013.js" type="text/javascript"></script>

<script src="g" async="" type="text/javascript"></script><script type="text/javascript" src="monetate.js"></script>






<title>HIV Drug Resistance — NEJM</title>
<meta name="description" content="Review Article from The New England Journal of Medicine — HIV Drug Resistance">

<meta name="pageType" content="Article">
<meta name="evt-pageType" content="Article">








   <meta property="og:title" content="HIV Drug Resistance — NEJM">
   <meta property="og:description" content="Review Article from The New England Journal of Medicine — HIV Drug Resistance">
   <meta property="og:type" content="article">
   <meta property="og:image" content="http://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2004/nejm_2004.350.issue-10/nejmra025195/production/images/small/nejmra025195_f1.gif">
   <meta name="twitter:card" content="summary">
   <meta name="twitter:site" content="@NEJM">



















	
	    <meta name="evt-doiPage" content="10.1056/NEJMra025195">
	
	
	
	    <meta name="evt-dt" content="2004-03-04">
	
	
	
	    <meta name="evt-ageContent" content="6Months-1990">
	
	
	
	    <meta name="evt-free" content="no">
	

	
		
				<meta name="evt-artView" content="full">
				
			
	
			
	
		<link rel="canonical" href="http://www.nejm.org.libgate.library.nuigalway.ie/doi/full/10.1056/NEJMra025195">
		
	
















<meta name="sessionEvt-individual" content="">
<meta name="sessionEvt-idGUID" content="">
<meta name="sessionEvt-freeCntry" content="">
<meta name="sessionEvt-instId" content="1452137">
<meta name="sessionEvt-audSegment" content="">
<meta name="sessionEvt-prodCode" content="">
<meta name="sessionEvt-nejmSource" content="">
<meta name="sessionEvt-offers" content="N-institution-currentArticles">






	








<!-- Load CSS via Ad Placeholders -->
<!-- placeholder id=null, description=N-config-css-global -->
<!-- placeholder id=null, description=N-config-css-ads -->

<script type="text/javascript" src="jquery.js"></script>
<script type="text/javascript" src="siteEditor.js"></script>
<script type="text/javascript" src="jquery.cookie.js"></script>
<script type="text/javascript" src="jquery.bbq.js"></script>
<script type="text/javascript" src="mmsEventMappings.js"></script>
<script type="text/javascript" src="mmsEvents.js"></script>
<script type="text/javascript" src="script.js"></script>
<script type="text/javascript" src="mmsFilterBanks.js"></script>
<script type="text/javascript" src="mmsMenus.js"></script>
<script type="text/javascript" src="mmsClassData.js"></script>
<script type="text/javascript" src="mmsAds.js"></script>
<script type="text/javascript" src="mmsCarousels.js"></script>
<script type="text/javascript" src="mmsUtilities.js"></script>
<script type="text/javascript" src="mmsTabPanel.js"></script>
<script type="text/javascript" src="mmsViews.js"></script>
<script type="text/javascript" src="mmsBoxy.js"></script>
<script type="text/javascript" src="jquery.form.js"></script>
<script type="text/javascript" src="swfobject.js"></script>
<script type="text/javascript" src="jquery.dimensions.js"></script>
<script type="text/javascript" src="jquery.cluetip.js"></script>
<script type="text/javascript" src="jquery.highlight.js"></script>
<script type="text/javascript" src="jquery.jcarousel.js"></script>
<script type="text/javascript" src="jquery-ui-1.7.2.custom.min.js"></script>
<script type="text/javascript" src="mmsLayers.js"></script>
<script type="text/javascript" src="mmsAddThis.js"></script>

<!--[if IE]><script language="javascript" type="text/javascript" src="http://cdn.nejm.org.libgate.library.nuigalway.ie/5.2/js/lib/excanvas.min.js"></script><![endif]-->






<!--[if lte IE 6]><script type="text/javascript" src="http://cdn.nejm.org.libgate.library.nuigalway.ie/5.2/js/DD_belatedPNG.js"></script><![endif]-->
<script type="text/javascript" src="ntpagetag.js"></script><script src="unica_eluminate.js" type="text/javascript"></script>

<script type="text/javascript">var _sf_startpt=(new Date()).getTime()</script>

<!-- Load JS via Ad Placeholders -->
<!-- placeholder id=null, description=N-config-js-global-top -->

<script async="" src="1796495826" type="text/javascript"></script><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><div id="_atssh" style="visibility: hidden; height: 1px; width: 1px; position: absolute; z-index: 100000;"><iframe src="NEJMra025195_1.html" style="height: 1px; width: 1px; position: absolute; z-index: 100000; border: 0px none; left: 0px; top: 0px;" title="AddThis utility frame" id="_atssh225"></iframe></div><script src="core078.js" type="text/javascript"></script>
<link rel="stylesheet" type="text/css" href="NEJMra025195.css" media="all">
</head>
<body class="article">

<div id="dic_bubble" class="selection_bubble fontSize13 noSelect" style="z-index: 9999; border: 1px solid rgb(74, 174, 222);"></div><noscript>

<img src="http://pt000185.unica.com/ntpagetag.gif?site=nejm&js=0" height="1" width="1" border="0" hspace="0" vspace="0" alt=" ">
</noscript>





<script type="text/javascript">

   
    var servicesURL="http://imc.nejm.org/ExamService/ExamService.asmx";
</script>


















<script type="text/javascript">

    var CM8Server = "web.checkm8.com";
    var CM8Cat = "mms.nej.articles";
    var CM8Profile = "pharma=no&articlecat=review";
</script>
<script type="text/javascript" language="JavaScript" src="cm8adam_1_ajax.js"></script>



<!--[if lte IE 6]><div class="ie6and7" id="ie6"><![endif]-->
<!--[if IE 7]><div class="ie6and7" id="ie7"><![endif]-->
<!--[if IE 8]><div id="ie8"><![endif]-->















<div id="topAdBar">
<div class="bannerAd">
<div class="inner">














<div id="CM8ShowAd1369757136140" title="Topbanner" class="Topbanner CM8">
<noscript><a href="http://web.checkm8.com/adam/ep/click/mms.nej.articles/Topbanner"><img src="http://web.checkm8.com/adam/noscript?cat=mms.nej.articles&amp;page=1369757136140&amp;format=Topbanner" border="0" alt="Advertisement" /></a></noscript>

</div></div>
</div>
</div>






<div style="margin-top: 30px;" align="center">
    <!-- placeholder id=null, description=N-ad-global-top --><div style="background: none repeat ; 0% rgb(255, 255, 255); padding: 0px; width: 970px; height: 20px; margin: 0px auto 10px;" align="left"><p style="font: 11px/15px arial,sans-serif; color: rgb(51, 51, 51);">Learn how NEJM.org uses cookies at the <a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3528&amp;url=%2Fpage%2Fabout-nejm%2Fcookie-information&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Cookie Information</a> page.</p></div>
</div>











<script type="text/javascript">

    $(document).ready(function() {
        $("#lnkSignOut").click(function(){
            $.cookie("redirectUri",null, {path: '/', domain: '.nejm.org'});
        });
    })
</script>

<div id="authInfo">

    <!-- placeholder id=null, description=N-ad-global-top-left -->
        <!-- topLeftAniv -->
            <div class="topLeftAniv">
             
            </div>
        <!-- /topLeftAniv -->
    

    <ul>
        
        
                
                        <li class="status firstChild">Welcome</li>
                    
            

        
        <!-- placeholder id=null, description=N-ad-authstring -->
            <li class="authOptions">
            <span class="renewSubscribe"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=4972&amp;url=%2Faction%2FcdfProxy%3Faction%3Drenew%26promo%3DONFLRNA2&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800" class="renew">Renew</a>, <a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=4972&amp;url=%2Faction%2FcdfProxy%3Faction%3Dsubscribe%26promo%3DONFQN1A2&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800" class="subscribe">Subscribe</a> or <a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=4972&amp;url=%2Faction%2FcdfProxy%3Faction%3Dregister%26promo%3DONFLNAR3&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800" class="createAccount">Create Account</a></span>
            </li>
        

        
        
                <li class="signin lastChild">
                    
                            <a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showLogin?uri=http%3A%2F%2Fwww.nejm.org%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195" class="viewType-Layer viewClass-WideLayer signin-header">

                                
                                        
                                    
                                Sign In
                            </a>
                        
                </li>
            

    </ul>
</div>






<div id="header" class="withAd">
	<h1><a href="http://www.nejm.org.libgate.library.nuigalway.ie/">The New England Journal of Medicine</a></h1>
    
        <!-- placeholder id=null, description=N-ad-header-1 -->
            <div class="ad"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3944&amp;url=%2Faction%2FcdfProxy%3Faction%3Dsubscribe%26url%3Dhttp%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMra025195%26promo%3DONFQRN03&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800"><img src="DefaultSubscribe_SubscribeOrRenew_Cover_280x83.jpg">
</a></div>
        
    
</div>






	

<div style="position: relative;" id="topNav">
<ul>
<li class="firstChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/">Home</a></li>
<li class="menu dropDownTrigger-articles"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/medical-article-index">Articles &amp; Multimedia</a></li>
<li class="menu dropDownTrigger-issueArchive"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/medical-index">Issues</a></li>
<li class="menu dropDownTrigger-topics"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/medical-specialties">Specialties &amp; Topics</a></li>
<li class="menu authors dropDownTrigger-authors"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/cdfProxy?action=authorCenter">For Authors</a></li>
<li class="menu cmeButton lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/continuing-medical-education">CME</a></li>
</ul>
    <form action="http://www.nejm.org.libgate.library.nuigalway.ie/search?pageType=search" class="search" method="get"><fieldset>
    <div style="position: absolute; left: 654px; top: 23px; width: 225px; visibility: hidden; z-index: 99999999;" class="autocomplete"></div><input id="sli_search_1" class="text" name="q" value="Keyword, Title, Author, or Citation" size="15" maxlength="450" autocomplete="off" type="text">	
	<input class="searchSubmit" value="Search" src="search_icon.gif" type="image">
    <input disabled="" name="asug" value="" type="hidden">
    <a href="http://www.nejm.org.libgate.library.nuigalway.ie/medical-search" class="more advSearch">Advanced<br>Search</a>
    </fieldset></form>
</div>

<div id="main">

    <div id="content">

    
    




    <a name="articleTop" rel="10.1056/NEJMra025195"></a><p class="articleType">Review Article</p><p class="seriesTitle">Medical Progress</p><h1>HIV Drug Resistance</h1><p class="authors">François Clavel, M.D., and Allan J. Hance, M.D.</p><p class="citationLine"><span class="citation">N Engl J Med 2004;  350:1023-1035</span><a href="http://www.nejm.org.libgate.library.nuigalway.ie/toc/nejm/350/10/">March 4, 2004</a><span class="doi">DOI:  10.1056/NEJMra025195</span></p><!--DiscussionPollOpenDateReplacer--><!-- share -->
<div class="share addthis_toolbox no-pad-bot" addthis:url="http://www.nejm.org/doi/full/10.1056/NEJMra025195">
    <div class="cols">
        <div class="col"><span class="label">Share:</span></div>
        <div class="col">
            <a href="#" title="Facebook" class="addthis_button_facebook at300b"><span class="icon add facebook"></span></a>
        </div>
        <div class="col">
            <a href="#" title="Tweet" class="addthis_button_twitter at300b"><span class="icon add twitter"></span></a>
        </div>
        <div class="col">
            <a title="Google+" target="_top" href="http://www.addthis.com/bookmark.php?v=300&amp;winname=addthis&amp;pub=ra-4ddfaaf00b1e6fbf&amp;source=tbx-300&amp;lng=en-US&amp;s=google_plusone_share&amp;url=http%3A%2F%2Fwww.nejm.org%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;title=HIV%20Drug%20Resistance%20%E2%80%94%20NEJM&amp;ate=AT-ra-4ddfaaf00b1e6fbf/-/-/51a4d5e35ffd5129/2&amp;frommenu=1&amp;uid=51a4d5e36feba22a&amp;ct=1&amp;ui_cobrand=NEJM.org&amp;pre=http%3A%2F%2Fwww.nejm.org%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;tt=0&amp;captcha_provider=nucaptcha" class="addthis_button_google_plusone_share at300b"><span class="icon add google"></span></a>
        </div>
        <div class="col">
            <a title="Linkedin" target="_top" href="http://www.addthis.com/bookmark.php?v=300&amp;winname=addthis&amp;pub=ra-4ddfaaf00b1e6fbf&amp;source=tbx-300&amp;lng=en-US&amp;s=linkedin&amp;url=http%3A%2F%2Fwww.nejm.org%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;title=HIV%20Drug%20Resistance%20%E2%80%94%20NEJM&amp;ate=AT-ra-4ddfaaf00b1e6fbf/-/-/51a4d5e35ffd5129/3&amp;frommenu=1&amp;uid=51a4d5e3f497b582&amp;shortener=bitly&amp;bitly.login=nejm&amp;bitly.apiKey=R_644f2c9aae1c9bcb164b6f24392c94f4&amp;ct=1&amp;ui_cobrand=NEJM.org&amp;pre=http%3A%2F%2Fwww.nejm.org%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;tt=0&amp;captcha_provider=nucaptcha" class="addthis_button_linkedin at300b"><span class="icon add linkedin"></span></a>
        </div>
        <div class="col">
            <a class="addthis_button"><span class="icon add addmore"></span></a>
        </div>
    </div>
<div class="atclear"></div></div>
<!-- /share --><dl class="articleTabs tabPanel lastChild"><dt class="active article firstChild sideBySide" id="articleTab">Article</dt><dt class="references sideBySide inactive" id="referencesTab">References</dt><dt class="citedby sideBySide inactive" id="citedbyTab">Citing Articles <span>(4) </span></dt><!--DiscussionReplacer_Tab_--><dt class="letters sideBySide inactive" id="lettersTab">Letters</dt><dd style="display: block;" id="article"><div class="section"> <p>The use of combinations of antiretroviral drugs has proven remarkably effective in controlling the progression of human immunodeficiency virus (HIV) disease and prolonging survival,<span class="ref"><a href="#ref1" class="showRefLayer" rel="#refLayer">1</a></span> but these benefits can be compromised by the development of drug resistance.<span class="ref"><a href="#ref2" class="showRefLayer" rel="#refLayer">2,3</a></span> Resistance is the consequence of mutations that emerge in the viral proteins targeted by antiretroviral agents. In the United States, as many as 50 percent of patients receiving antiretroviral therapy are infected with viruses that express resistance to at least one of the available antiretroviral drugs.<span class="ref"><a href="#ref4" class="showRefLayer" rel="#refLayer">4</a></span> Consequently, the transmission of drug-resistant strains is also a growing concern.<span class="ref"><a href="#ref5" class="showRefLayer" rel="#refLayer">5-7</a></span> Because drug-resistant HIV often exhibits resistance to several classes of antiretroviral drugs<span class="ref"><a href="#ref8" class="showRefLayer" rel="#refLayer">8</a></span> and because cross-resistance between drugs within a class is frequent,<span class="ref"><a href="#ref9" class="showRefLayer" rel="#refLayer">9-12</a></span> the emergence of resistance always complicates further efforts to control viral replication. This review focuses on the mechanisms underlying the selection of drug-resistant HIV and on the consequences of viral resistance with respect to the evolution of HIV infection.</p> </div><div class="section"> <h3 id="articlePrinciples of Drug Therapy for HIV">Principles of Drug Therapy for HIV</h3> <p>The drugs currently used to treat HIV type 1 (HIV-1) infection (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=t01">Table 1</a><span class="table"><span class="figureTitle">Table 1</span><a class="figureLink viewType-Layer viewClass-ImageViewerLayer event-articleThumb" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=t01"><img src="nejmra025195_t1.gif" alt=""></a><span class="figureCaption">Antiretroviral Agents Used in the Treatment of HIV Infection.</span></span>) belong to four distinct classes: nucleoside and nucleotide analogues, which act as DNA-chain terminators and inhibit reverse transcription of the viral RNA genome into DNA, a crucial event occurring at an early stage of the viral life cycle; nonnucleoside reverse-transcriptase inhibitors, which bind and inhibit reverse transcriptase, the viral enzyme that conducts reverse transcription; protease inhibitors, which target the viral protease, the enzyme required for the cleavage of precursor proteins (gag and gag–pol), permitting the final assembly of the inner core of viral particles; and entry inhibitors, which block the penetration of HIV virions into their target cells. Combinations of antiretroviral drugs are now used for the treatment of HIV infection — so-called highly active antiretroviral therapy (HAART). Current HAART regimens generally comprise three antiretroviral drugs, usually two nucleoside analogues and either a protease inhibitor or a nonnucleoside reverse-transcriptase inhibitor.<span class="ref"><a href="#ref13" class="showRefLayer" rel="#refLayer">13</a></span> The use of agents from different classes is instrumental in controlling the development of resistance, but whereas some drug combinations have been shown to be antagonistic, there is no evidence that any combinations of currently available drugs are strongly synergistic in vitro.</p> </div><div class="section"> </div><div class="section"> <h3 id="articleDevelopment of Resistance">Development of Resistance</h3> <div class="subSection"> <h3 id="articleInduced Resistance">Induced Resistance</h3> <p>Two concepts are important to an understanding of the development of drug resistance. First, HIV infection is characterized by high levels of virus production and turnover. In most untreated patients, the total number of productively infected cells in the lymphoid tissue has been estimated to be approximately 10<sup>7</sup> to 10<sup>8</sup> cells.<span class="ref"><a href="#ref14" class="showRefLayer" rel="#refLayer">14</a></span> During the chronic phase of HIV infection, this number is relatively stable, reflecting the balance between the infection of new target cells and their clearance. Because the half-life of infected cells is remarkably short (one to two days), the maintenance of this steady state requires that HIV infect new target cells at a very high rate.<span class="ref"><a href="#ref15" class="showRefLayer" rel="#refLayer">15-17</a></span> Second, the viral population in an infected person is highly heterogeneous.<span class="ref"><a href="#ref18" class="showRefLayer" rel="#refLayer">18</a></span> The reverse transcription of viral RNA into DNA is notoriously prone to error,<span class="ref"><a href="#ref19" class="showRefLayer" rel="#refLayer">19,20</a></span> introducing on average one mutation for each viral genome transcribed. Most of these errors are base substitutions, but duplications, insertions, and recombination can also occur. The high rate of HIV infection, combined with the high mutation rate that occurs during each cycle of infection, ensures that patients have a complex and diverse mixture of viral quasispecies, each differing by one or more mutations.</p> <p>Under these circumstances, it is easy to understand why if any of these mutations can confer some selective advantage to the virus, such as a decrease in its susceptibility to an antiretroviral agent, the corresponding quasispecies will overtake the others, following a simple darwinian selection process. The rapidity of this process depends on the level of the selective advantage conferred by the mutation, the prevalence of the mutant within the virus population, and the level of drug at the site of HIV replication. In some cases, substitutions of single amino acids can produce high levels of resistance. Since minority viral quasispecies carrying any single mutation are believed to exist even before treatment is started,<span class="ref"><a href="#ref21" class="showRefLayer" rel="#refLayer">21</a></span> the emergence of these highly resistant single mutants can occur in a matter of weeks. For other agents, only low-level resistance can be induced by single mutations. In these cases, high levels of resistance or complete resistance requires the gradual accumulation of additional mutations.</p> <p>Combination therapy can block this selection process for two reasons. First, multiple mechanisms (each requiring different mutations) are required for resistance to occur to all drugs in the regimen. Even if a small number of variants with the potential for resistance to individual agents exist before treatment, it is highly unlikely that some of these variants are able to resist all the drugs. Second, multiple drugs suppress viral replication more effectively than single agents.<span class="ref"><a href="#ref22" class="showRefLayer" rel="#refLayer">22,23</a></span> In the absence of ongoing viral replication, the generation of new variants is also arrested. In patients who receive HAART as a first line of antiretroviral therapy, the emergence of viral resistance is possible only if HIV continues to replicate in the presence of levels of drugs that are insufficient to block viral replication but sufficient to exert a positive selective pressure on variants with decreased drug susceptibility. Under these conditions, viruses with resistance to all the components of the regimen will gradually emerge. Thus, it is worth emphasizing that in the context of HAART, resistance is most often the consequence — not the cause — of initial treatment failure. Once resistance begins to develop, however, a vicious circle of increasing treatment failure and increasing levels of resistance can lead to situations in which it becomes impossible to control viral replication with currently available drugs.</p> </div> <div class="subSection"> <h3 id="articlePrimary Resistance">Primary Resistance</h3> <p>Patients primarily infected with HIV strains that exhibit resistance to zidovudine were identified as early as 1993, six years after zidovudine was introduced as the first antiretroviral drug active against HIV.<span class="ref"><a href="#ref24" class="showRefLayer" rel="#refLayer">24</a></span> Since HAART became available in 1996, a number of reports have described the transmission of HIV strains with resistance to single or multiple antiretroviral drugs.<span class="ref"><a href="#ref5" class="showRefLayer" rel="#refLayer">5-7</a></span> The prevalence of primary HIV resistance appears to be quite variable in different communities, but there is a trend toward an increase.<span class="ref"><a href="#ref6" class="showRefLayer" rel="#refLayer">6,7</a></span> Although most such cases involve the transmission of strains of HIV-1 from patients in whom resistance has developed during therapy, some strains of HIV are naturally resistant to some antiretroviral drugs. For example, HIV type 2 (HIV-2) is intrinsically resistant to most nonnucleoside reverse-transcriptase inhibitors.<span class="ref"><a href="#ref25" class="showRefLayer" rel="#refLayer">25</a></span> Similarly, some subtypes of HIV-1 can be less susceptible to protease inhibitors or nonnucleoside reverse-transcriptase inhibitors than the subtype B strains that are prevalent in the United States and Europe.<span class="ref"><a href="#ref26" class="showRefLayer" rel="#refLayer">26-29</a></span> More information is needed on the natural susceptibility of non-B subtypes and on the patterns of resistance mutations that occur in these strains, which can differ from those observed with subtype B. Because non-B subtypes are dominant in Africa and Asia, particular care in the choice of antiretroviral regimens must be exercised in those regions.</p> </div> </div><div class="section"> </div><div class="section"> <h3 id="articleMechanisms of Resistance">Mechanisms of Resistance</h3> <p>Considerable progress has been made in identifying mutations associated with drug resistance (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=t02">Table 2</a><span class="table"><span class="figureTitle">Table 2</span><a class="figureLink viewType-Layer viewClass-ImageViewerLayer event-articleThumb" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=t02"><img src="nejmra025195_t2.gif" alt=""></a><span class="figureCaption">Mutations Involved in Resistance of HIV to Nucleoside Analogues, Nonnucleoside Reverse-Transcriptase Inhibitors (NNRTIs), and Protease Inhibitors.</span></span>) and in understanding the mechanisms through which they confer resistance (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=t01">Table 1</a>). A variety of mechanisms have been identified that differ both for different classes of drugs and for drugs of a given class. The locations of drug-resistance mutations in reverse transcriptase and in protease are shown in <a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=f01">Figure 1</a><span class="fig"><span class="figureTitle">Figure 1</span><a class="figureLink viewType-Layer viewClass-ImageViewerLayer event-articleThumb" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=f01"><img src="nejmra025195_f1.gif" alt=""></a><span class="figureCaption">Complex of HIV-1 Reverse Transcriptase with an RNA–DNA Duplex.</span></span> and <a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=f03">Figure 3A</a><span class="fig"><span class="figureTitle">Figure 3</span><a class="figureLink viewType-Layer viewClass-ImageViewerLayer event-articleThumb" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=f03"><img src="nejmra025195_f3.gif" alt=""></a><span class="figureCaption">HIV-1 Protease Dimer Binding with a Protease Inhibitor (Panel A) and a Drug-Sensitive (Wild-Type) Protease Juxtaposed against a Drug-Resistant Protease (Panel B).</span></span>, respectively.</p> <div class="subSection"> <h3 id="articleResistance to Nucleoside and Nucleotide Analogues">Resistance to Nucleoside and Nucleotide Analogues</h3> <p>Nucleoside analogues and nucleotide analogues (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=t01">Table 1</a>) arrest the synthesis of viral DNA by reverse transcriptase. After phosphorylation by cellular kinases, these compounds are incorporated by reverse transcriptase into the nascent chain of viral DNA. Because these drugs lack a 3' hydroxyl group, no additional nucleotides can be attached to them, and the synthesis of viral DNA is arrested. Two distinct mechanisms are involved in HIV resistance to these drugs: impairment of the incorporation of the analogue into DNA and removal of the analogue from the prematurely terminated DNA chain.</p> <div class="subSection"> <h3 id="articleImpairment of Analogue Incorporation">Impairment of Analogue Incorporation</h3> <p>Several mutations or groups of mutations in reverse transcriptase can promote resistance by selectively impairing the ability of reverse transcriptase to incorporate an analogue into DNA (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=f02">Figure 2A</a><span class="fig"><span class="figureTitle">Figure 2</span><a class="figureLink viewType-Layer viewClass-ImageViewerLayer event-articleThumb" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=f02"><img src="nejmra025195_f2.gif" alt=""></a><span class="figureCaption">The Two Principal Mechanisms of Resistance of HIV to Nucleoside Analogues.</span></span>). They essentially include the M184V mutation, the Q151M complex of mutations, and the K65R mutation (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=t02">Table 2</a>).</p> <p>The M184V mutation involves the replacement of methionine by valine at position 184 of the reverse transcriptase and is the main mutation that confers resistance to lamivudine.<span class="ref"><a href="#ref31" class="showRefLayer" rel="#refLayer">31</a></span> Methionine 184 is located at the heart of the catalytic site of reverse transcriptase, and its replacement by a valine, which has a different side chain, interferes with the proper positioning of lamivudine triphosphate within the catalytic site (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=f01">Figure 1</a> and <a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=f02">Figure 2A</a>).<span class="ref"><a href="#ref32" class="showRefLayer" rel="#refLayer">32</a></span> The M184V mutation induces very high levels of resistance to lamivudine. When lamivudine is used as a single agent, resistant strains overtake wild-type virus in a few weeks,<span class="ref"><a href="#ref33" class="showRefLayer" rel="#refLayer">33</a></span> and when lamivudine is used as part of a failing regimen of HAART, the M184V mutation is almost always the first mutation to emerge.<span class="ref"><a href="#ref34" class="showRefLayer" rel="#refLayer">34,35</a></span> </p> <p>The group of mutations referred to as the Q151M complex<span class="ref"><a href="#ref36" class="showRefLayer" rel="#refLayer">36</a></span> (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=t02">Table 2</a>) is most often selected for in the course of the failure of regimens containing stavudine and didanosine. This pathway always starts with the Q151M substitution, a residue located in the immediate vicinity of the nucleotide-binding site of reverse transcriptase, and is followed by the gradual accumulation of secondary mutations that enhance resistance and increase the activity of the enzyme.<span class="ref"><a href="#ref37" class="showRefLayer" rel="#refLayer">37</a></span> The Q151M complex is relatively rare in HIV-1 (fewer than 5 percent of all HIV strains with resistance to nucleoside analogues) but can confer high-level resistance to most — but not all (e.g., lamivudine and tenofovir) — analogues.<span class="ref"><a href="#ref36" class="showRefLayer" rel="#refLayer">36</a></span> Interestingly, the Q151M complex is markedly more frequent in HIV-2 than in HIV-1.</p> <p>The K65R mutation is seen with increasing frequency in patients in whom therapy with nucleoside or nucleotide analogues fails, especially when the regimen includes tenofovir or abacavir. This mutation appears to confer resistance to most analogues, with the exception of zidovudine.</p> </div> <div class="subSection"> <h3 id="articleRemoval of the Analogue from the Terminated DNA Chain">Removal of the Analogue from the Terminated DNA Chain</h3> <p>Removal of the nucleoside analogue from the terminated DNA chain is associated with a group of mutations commonly termed “thymidine analogue mutations” (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=t02">Table 2</a>). Mutations from this group are most frequently selected for after the failure of drug combinations that include thymidine analogues, such as zidovudine and stavudine, but they can promote resistance to almost all nucleoside and nucleotide analogues, including tenofovir.<span class="ref"><a href="#ref38" class="showRefLayer" rel="#refLayer">38-41</a></span> These mutations occur gradually, and their order of emergence can vary.<span class="ref"><a href="#ref10" class="showRefLayer" rel="#refLayer">10,42</a></span> Thymidine analogue mutations promote resistance by fostering ATP- or pyrophosphate-mediated removal of nucleoside analogues from the 3' end of the terminated DNA strand (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=f02">Figure 2B</a>).<span class="ref"><a href="#ref43" class="showRefLayer" rel="#refLayer">43,44</a></span> ATP and pyrophosphate, which are abundant in normal lymphocytes, do not participate in the DNA-polymerization reaction, but the structure of a reverse transcriptase expressing thymidine analogue mutations facilitates their entry into a site adjacent to the incorporated analogue.<span class="ref"><a href="#ref45" class="showRefLayer" rel="#refLayer">45,46</a></span> In this position, ATP or pyrophosphate can attack the phosphodiester bond that links the analogue to DNA, resulting in removal of the analogue (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=f02">Figure 2B</a>). Interestingly, the efficiency of this process, also known as “primer rescue,” can be significantly decreased by the presence of other mutations in reverse transcriptase, a phenomenon that has been best described in the case of the M184V mutation.<span class="ref"><a href="#ref47" class="showRefLayer" rel="#refLayer">47</a></span> As a consequence, M184V slows the selection of thymidine analogue mutations by thymidine analogues<span class="ref"><a href="#ref41" class="showRefLayer" rel="#refLayer">41</a></span> and may slightly increase the residual antiviral activity of some nucleoside analogues in spite of the presence of thymidine analogue mutations.</p> </div> </div> <div class="subSection"> <h3 id="articleResistance to Nonnucleoside Reverse-Transcriptase Inhibitors">Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors</h3> <p>Nonnucleoside reverse-transcriptase inhibitors are small molecules that have a strong affinity for a hydrophobic pocket located close to the catalytic domain of the reverse transcriptase (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=f01">Figure 1</a> and <a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=f04">Figure 4</a><span class="fig"><span class="figureTitle">Figure 4</span><a class="figureLink viewType-Layer viewClass-ImageViewerLayer event-articleThumb" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=f04"><img src="nejmra025195_f4.gif" alt=""></a><span class="figureCaption">Mechanism of Resistance of HIV to Nonnucleoside Reverse-Transcriptase Inhibitors.</span></span>). The binding of the inhibitors affects the flexibility of the enzyme, thereby blocking its ability to synthesize DNA.<span class="ref"><a href="#ref48" class="showRefLayer" rel="#refLayer">48</a></span> The mutations that are selected for after the failure of treatment with nonnucleoside reverse-transcriptase inhibitors are all located in the pocket targeted by these compounds, and they reduce the affinity of the drug.<span class="ref"><a href="#ref48" class="showRefLayer" rel="#refLayer">48-53</a></span> Because of subtle differences in the interaction between various nonnucleoside reverse-transcriptase inhibitors and the hydrophobic pocket,<span class="ref"><a href="#ref51" class="showRefLayer" rel="#refLayer">51</a></span> however, the mutations that emerge most frequently are somewhat drug-dependent (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=t02">Table 2</a>). Resistance to nevirapine is often associated with the Y181C mutation, but other mutations, such as Y188C, K103N, G190A, and V106A, also occur. Initial resistance to efavirenz is generally characterized by the K103N mutation, but the Y188L mutation is also seen.</p> </div> <div class="subSection"> <h3 id="articleResistance to Protease Inhibitors">Resistance to Protease Inhibitors</h3> <p>The HIV protease cleaves large polyprotein precursors at specific sites, releasing the structural proteins and enzymes necessary for the assembly of infectious viral particles. In the absence of a functional protease, viral particles are produced, but they are immature and are not infectious. The protease of HIV is a symmetrically assembled homodimer with a central, symmetric, substrate-binding cavity (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=f03">Figure 3A</a>). Detailed knowledge of the structure of this domain and of the structure of the natural protein substrates of the enzyme has led to the design of specific inhibitors whose chemical structure mimics that of the viral peptides that are normally recognized and cleaved by the protease.<span class="ref"><a href="#ref54" class="showRefLayer" rel="#refLayer">54,55</a></span> These compounds display a strong affinity for the active site of the HIV protease and inhibit the catalytic activity of the enzyme in a highly selective manner.</p> <p>Resistance to protease inhibitors is the consequence of amino acid substitutions that emerge either inside the substrate-binding domain of the enzyme or at distant sites<span class="ref"><a href="#ref56" class="showRefLayer" rel="#refLayer">56-58</a></span> (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=t02">Table 2</a> and <a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=f03">Figure 3A</a>). Directly or indirectly, these amino acid changes modify the number and the nature of the points of contact between the inhibitors and the protease, thereby reducing their affinity for the enzyme.<span class="ref"><a href="#ref59" class="showRefLayer" rel="#refLayer">59-62</a></span> As an example, the common resistance mutation V82A reduces the size of an amino acid residue in the protease that is more important for binding most inhibitors than for binding the natural viral protein substrate (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=f03">Figure 3A</a>).<span class="ref"><a href="#ref62" class="showRefLayer" rel="#refLayer">62</a></span> Protease inhibitors have been designed to bind the protease with maximal affinity and tend to occupy more space inside the active site cavity than do natural substrates. Unlike the inhibitors, the natural substrates of the protease have a variable, but generally less tight, interaction with the catalytic site, a phenomenon that promotes the ordered sequential cleavage of the polyproteins required for proper assembly of the viral particle. Resistance mutations in the protease, which result in an overall enlargement of the catalytic site of the enzyme (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=f03">Figure 3B</a>), would thus be predicted to have a greater effect on the binding of inhibitors than the natural templates.</p> <p>Some mutations are selected for only by certain protease inhibitors (<a class="viewType-Layer viewClass-ImageViewerLayer" href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showImage?doi=10.1056%2FNEJMra025195&amp;iid=t02">Table 2</a>), reflecting particularities in the chemical structure of the inhibitors that influence their interaction with the substrate-binding domain of the enzyme. However, there is considerable overlap between the combinations of mutations in HIV strains that develop resistance to protease inhibitors. This overlap explains the wide cross-resistance that is generally observed within this drug class.<span class="ref"><a href="#ref9" class="showRefLayer" rel="#refLayer">9,12,63</a></span> Remarkably, resistance to protease inhibitors can also be promoted by mutations in some of the natural viral substrates of the protease.<span class="ref"><a href="#ref64" class="showRefLayer" rel="#refLayer">64-66</a></span> Characteristic substitutions of amino acids near cleavage sites of the gag polyprotein have been identified that can increase the level of resistance and the replicative capacity of the virus by facilitating cleavage under conditions in which the amount of active enzyme is suboptimal or improving the ability of proteases containing resistance mutations to interact with the substrate.</p> </div> <div class="subSection"> <h3 id="articleResistance to Fusion Inhibitors">Resistance to Fusion Inhibitors</h3> <p>HIV-1 enters target cells through an intricate sequence of interactions between the HIV envelope glycoprotein (gp) complex (gp120–gp41) and specific cell-surface receptors.<span class="ref"><a href="#ref67" class="showRefLayer" rel="#refLayer">67</a></span> The early steps in this process allow gp41, the fusogenic component of the complex, to interact with the cell membrane, thereby tethering the virus to its target. The membranes of the virus and target cell are then brought into close proximity, fostering their fusion, by further rearrangement of gp41. In this step, a distal hydrophobic region of gp41, HR2, folds onto a more proximal hydrophobic region, HR1, effectively shortening the molecule. Enfuvirtide, a 36-amino-acid peptide derived from HR2, destabilizes this process by binding to HR1 and blocks the infectivity of HIV-1. Viral resistance to enfuvirtide usually results from mutations located in a stretch of 10 amino acids within HR1.<span class="ref"><a href="#ref68" class="showRefLayer" rel="#refLayer">68,69</a></span> Interestingly, changes in amino acids in gp41 outside HR1 — and even changes in gp120 — appear to be associated with significant differences in the susceptibility of the virus to enfuvirtide.<span class="ref"><a href="#ref70" class="showRefLayer" rel="#refLayer">70,71</a></span> These mutations or polymorphisms probably explain the remarkably wide range of natural susceptibility to enfuvirtide among HIV-1 strains<span class="ref"><a href="#ref70" class="showRefLayer" rel="#refLayer">70-72</a></span> and could participate in the evolution of acquired resistance to enfuvirtide.</p> </div> </div><div class="section"> </div><div class="section"> <h3 id="articleCross-Resistance">Cross-Resistance</h3> <p>Cross-resistance, defined as resistance to drugs to which a virus has never been exposed, results from mutations that have been selected for by the use of another drug. Cross-resistance is always restricted to drugs within a given class of antiretroviral agents, but all three classes of antiretroviral drugs are affected. Early in the evolution of resistance to nucleoside analogues or protease inhibitors, viruses may have only a low level of cross-resistance to alternative agents within each of these two classes of drugs.<span class="ref"><a href="#ref10" class="showRefLayer" rel="#refLayer">10,12</a></span> Nevertheless, these strains may need to add only one or a few additional mutations to this preexisting scaffolding for high-level cross-resistance to develop. Therefore, in patients infected with strains that have low levels of cross-resistance, the switch to apparently active alternative drugs can be accompanied by rapid selection for highly resistant variants, at the expense of minimal evolutionary changes.<span class="ref"><a href="#ref73" class="showRefLayer" rel="#refLayer">73,74</a></span> </p> </div><div class="section"> </div><div class="section"> <h3 id="articleEvolution of Resistance">Evolution of Resistance</h3> <p>Resistance is not an all-or-nothing phenomenon and generally increases over time.<span class="ref"><a href="#ref10" class="showRefLayer" rel="#refLayer">10,75,76</a></span> Single mutations rarely produce complete resistance to antiretroviral drugs, although the M184V mutation in reverse transcriptase, which results in complete resistance to lamivudine, is an exception to this rule. Single mutations in the hydrophobic pocket of reverse transcriptase also provide strong resistance to nonnucleoside reverse-transcriptase inhibitors, but the viral strains in patients in whom regimens using these drugs are failing often incur additional mutations, suggesting that the level of resistance provided by single mutations is not optimal.<span class="ref"><a href="#ref50" class="showRefLayer" rel="#refLayer">50,77</a></span> </p> <p>Resistance to reverse-transcriptase inhibitors through the accumulation of thymidine analogue mutations or Q151M complex mutations and resistance to protease inhibitors are always gradual processes, leading to progressive increases in the level of resistance.<span class="ref"><a href="#ref58" class="showRefLayer" rel="#refLayer">58,78</a></span> Nonetheless, even after several mutations have accumulated in the HIV protease and reverse transcriptase sufficient to produce patent treatment failure, resistance may not have reached maximal levels, and additional mutations, associated with increases in resistance, can occur even in the absence of any changes in treatment.<span class="ref"><a href="#ref75" class="showRefLayer" rel="#refLayer">75</a></span> Indeed, the development of complete resistance may represent an exception. Because resistance mutations can impair viral replicative capacity, the solution adopted by the dominant viral population may entail making concessions in terms of resistance. Efforts are being made to evaluate the antiviral activity retained by individual drugs in the face of resistance mutations. Such knowledge may help in the treatment of patients infected with viruses that express resistance to multiple classes of drugs, since keeping HIV under some pharmacologic pressure may reduce its pathogenic potential.</p> </div><div class="section"> </div><div class="section"> <h3 id="articleEffect of Resistance on Viral Replicative and Pathogenic Capacity">Effect of Resistance on Viral Replicative and Pathogenic Capacity</h3> <p>Many resistance mutations impair viral replication. Because these mutations modify key viral proteins, they have deleterious effects of variable extent on protein function. Although some of these deficits can be partially corrected by compensatory mutations,<span class="ref"><a href="#ref57" class="showRefLayer" rel="#refLayer">57,79</a></span> viruses forced to develop higher levels of resistance under intense and continuous pressure by antiretroviral drugs often have a substantial impairment in their replicative capacity.<span class="ref"><a href="#ref75" class="showRefLayer" rel="#refLayer">75</a></span> The degree of replicative impairment conferred by resistance mutations is highly variable. The most crippling mutations appear to be those associated with resistance to protease inhibitors,<span class="ref"><a href="#ref65" class="showRefLayer" rel="#refLayer">65,80-82</a></span> but significant replicative defects can be related to mutations in reverse transcriptase that confer resistance to nucleoside analogues or nonnucleoside reverse-transcriptase inhibitors,<span class="ref"><a href="#ref83" class="showRefLayer" rel="#refLayer">83,84</a></span> as well as envelope mutations associated with resistance to enfuvirtide.</p> <p>The clinical effect of resistance-associated loss of viral replicative capacity is the subject of intense investigation. Several observations suggest that resistant viruses have lost some of their virulence. When antiretroviral treatment is interrupted in patients infected with HIV that is resistant to multiple drugs, the resistant strain is more or less rapidly replaced by wild-type virus. This change is accompanied by a drop in CD4 T-cell counts, suggesting that wild-type virus has a greater replicative and pathogenic potential.<span class="ref"><a href="#ref85" class="showRefLayer" rel="#refLayer">85</a></span> In a significant proportion of patients in whom HAART is failing, the CD4 T-cell counts remain significantly above pretreatment levels, despite the poor control of replication.<span class="ref"><a href="#ref86" class="showRefLayer" rel="#refLayer">86-88</a></span> Whether this apparent immunologic benefit of HAART in spite of patent virologic failure is the direct consequence of reduced viral pathogenicity, a sign of persistent residual activity of some drugs in the regimen, or both, remains to be elucidated. Consequently, therapeutic strategies that take advantage of resistance-associated loss of HIV replicative capacity have yet to be identified.</p> </div><div class="section"> </div><div class="section"> <h3 id="articleMinority and Archived Populations of Virus">Minority and Archived Populations of Virus</h3> <p>The dominant population of resistant virus in the plasma does not always reflect the complex diversity of viral quasispecies in patients in whom HAART is failing. Like the viral populations present in untreated HIV-infected persons,<span class="ref"><a href="#ref18" class="showRefLayer" rel="#refLayer">18</a></span> those present in patients in whom therapy is failing remain quite heterogeneous.<span class="ref"><a href="#ref89" class="showRefLayer" rel="#refLayer">89,90</a></span> Minority populations of virus expressing a variety of distinct combinations of resistance mutations are generally present and can continue to evolve.<span class="ref"><a href="#ref91" class="showRefLayer" rel="#refLayer">91</a></span> Thus, these populations serve as a reservoir for the generation of novel resistance genotypes that can ultimately supplant the previously dominant population. Furthermore, throughout the natural history of HIV infection, viral genomes are continually being archived as latently integrated proviruses in resting cells.<span class="ref"><a href="#ref92" class="showRefLayer" rel="#refLayer">92,93</a></span> When patients in whom drug resistance has developed are treated with alternative agents for long periods, the mutations associated with resistance to the initially prescribed drugs are often no longer detectable in viruses obtained from plasma samples. Nevertheless, if therapy with these drugs is later resumed, archived resistant strains can reemerge,<span class="ref"><a href="#ref94" class="showRefLayer" rel="#refLayer">94,95</a></span> as the cells harboring these viruses become activated.</p> </div><div class="section"> </div><div class="section"> <h3 id="articleTesting for Drug Resistance">Testing for Drug Resistance</h3> <p>When plasma viral load rises in spite of therapy, it is currently recommended that antiretroviral treatment be changed quickly.<span class="ref"><a href="#ref96" class="showRefLayer" rel="#refLayer">96,97</a></span> Because cross-resistance between antiretroviral drugs within each class is frequent, changes in treatment cannot be based on the simple assumption that HIV will remain susceptible to alternative drugs within a class that the patient has previously received. In an effort to facilitate the selection of efficacious alternative regimens, resistance tests evaluating the susceptibility of HIV to individual antiretroviral drugs have been developed. Two types of assays are currently available: genotypic assays, which detect the presence of resistance mutations, and phenotypic assays, which measure the susceptibility of the virus to various drugs in tissue-culture systems. A number of retrospective studies have attempted to validate the clinical relevance of the results of resistance tests.<span class="ref"><a href="#ref97" class="showRefLayer" rel="#refLayer">97,98</a></span> In general, resistance to a drug has been found to be associated with reduced responsiveness of HIV to the drug in vivo, but the finding of apparent susceptibility on resistance testing is a somewhat less reliable predictor of a good response. This common observation can be explained by a number of factors, including the imprecision of some of the assays, the short evolutionary distance required for some initially susceptible viruses to develop full cross-resistance to the new agents if viral replication is not completely suppressed,<span class="ref"><a href="#ref73" class="showRefLayer" rel="#refLayer">73,74</a></span> the existence of confounding variables such as the pharmacokinetics of individual drugs, and the presence of species of archived or minority viruses with alternative resistance profiles,<span class="ref"><a href="#ref89" class="showRefLayer" rel="#refLayer">89-91</a></span> which are usually not detected by the assays. Prospective, randomized studies have examined the clinical benefit of drug-resistance testing.<span class="ref"><a href="#ref97" class="showRefLayer" rel="#refLayer">97,98</a></span> These studies evaluated patients infected with viruses in different stages of the evolution of resistance and have yielded somewhat conflicting results, but most have demonstrated that genotypic testing provides at least a moderate benefit.</p> </div><div class="section"> </div><div class="section"> <h3 id="articlePerspectives">Perspectives</h3> <p>As the inevitable consequence of the incomplete suppression of HIV-1 replication by antiretroviral drugs, resistance is a permanent threat for patients who are undergoing antiretroviral treatment, and transmission of resistant viruses is becoming an important concern. Prevention of resistance is a priority that requires unrelenting patient education regarding the risks of resistance and the use of improved drug regimens that ensure optimal tolerance, adherence, and potency. Once established, resistance evolves, diversifies, and may become irreversible. Nonetheless, new drugs are becoming available that appear to retain substantial antiviral activity against HIV-1 strains that are resistant to multiple drugs. These are either drugs from existing classes that have increased potency and improved pharmacokinetic properties or drugs from new classes that are not susceptible to cross-resistance. Although preliminary data indicate that viral resistance to these new drugs can also develop,<span class="ref"><a href="#ref99" class="showRefLayer" rel="#refLayer">99,100</a></span> the lessons learned about the development of viral resistance to the currently available antiretroviral drugs may prove helpful in devising treatment strategies with optimized antiviral potency that can minimize the development of resistance to these new agents.</p> </div><div class="section"> </div><div class="section section-hr"></div><div class="section section-back"> <p>Dr. Clavel reports having served as a consultant for GlaxoSmithKline, Bristol-Myers Squibb, and Bioalliance Pharma; holding stock in Bioalliance Pharma; and serving as a lecturer for GlaxoSmithKline, Bristol-Myers Squibb, Roche, and Gilead.</p> </div><div class="section section-back"><div class="sourceInfo"><h3>Source Information</h3><p>From the Unité de Recherche Antivirale, Institut National de la Santé et de la Recherche Médicale, Unité 552, Hôpital Bichat–Claude Bernard, Paris.</p><p>Address reprint requests to Dr. Clavel at INSERM, U552, IMEA, Hôpital Bichat–Claude Bernard, 46 rue Henri Huchard, 75018 Paris, France, or at <a class="email" href="mailto:clavel@bichat.inserm.fr">clavel@bichat.inserm.fr</a>.</p></div></div><div class="section section-back lastChild"></div></dd><dd style="display: none;" id="references"><div class="section"><h3>References</h3><ol class="striped"><a name="ref1"></a><li class="odd" id="refItem1"><p class="number">1</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Palella FJ Jr</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Delaney KM</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Moorman AC</contrib>, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. <span class="NLM_source">N Engl J Med</span> 1998;338:853-860<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r001&amp;dbid=20&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1056%2FNEJM199803263381301" onclick="newWindow(this.href);return false">Free Full Text</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r001&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000072669800001" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r001&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=9516219" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref2"></a><li class="even" id="refItem2"><p class="number">2</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">DeGruttola V</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Dix L</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">D'Aquila R</contrib>, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. <span class="NLM_source">Antivir Ther</span> 2000;5:41-48<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r002&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000087183000009" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r002&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=10846592" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref3"></a><li class="odd" id="refItem3"><p class="number">3</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Ledergerber B</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Egger M</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Erard V</contrib>, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. <span class="NLM_source">JAMA</span> 1999;282:2220-2226<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r003&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1001%2Fjama.282.23.2220" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r003&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000084138600029" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r003&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=10605973" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref4"></a><li class="even" id="refItem4"><p class="number">4</p><p class="content">Richman D, Bozette S, Morton S, et al. The prevalence of antiretroviral drug resistance in the US. In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, December 16–19, 2001. Washington, D.C.: American Society for Microbiology, 2001. abstract.<br></p></li><a name="ref5"></a><li class="odd" id="refItem5"><p class="number">5</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Yerly S</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kaiser L</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Race E</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Bru JP</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Clavel F</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Perrin L</contrib>. Transmission of antiretroviral-drug-resistant HIV-1 variants. <span class="NLM_source">Lancet</span> 1999;354:729-733<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r005&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1016%2FS0140-6736%2898%2912262-6" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r005&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000082233000012" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r005&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=10475184" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref6"></a><li class="even" id="refItem6"><p class="number">6</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Little SJ</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Holte S</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Routy J-P</contrib>, et al. Antiretroviral-drug resistance among patients recently infected with HIV. <span class="NLM_source">N Engl J Med</span> 2002;347:385-394<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r006&amp;dbid=20&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1056%2FNEJMoa013552" onclick="newWindow(this.href);return false">Free Full Text</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r006&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000177672400002" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r006&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=12167680" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref7"></a><li class="odd" id="refItem7"><p class="number">7</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Grant RM</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hecht FM</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Warmerdam M</contrib>, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. <span class="NLM_source">JAMA</span> 2002;288:181-188<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r007&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1001%2Fjama.288.2.181" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r007&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000176711100018" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r007&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=12095382" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref8"></a><li class="even" id="refItem8"><p class="number">8</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Shafer RW</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Winters MA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Palmer S</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Merigan TC</contrib>. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. <span class="NLM_source">Ann Intern Med</span> 1998;128:906-911<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r008&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000073808600005" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r008&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=9634429" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref9"></a><li class="odd" id="refItem9"><p class="number">9</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hertogs K</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Bloor S</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kemp SD</contrib>, et al. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. <span class="NLM_source">AIDS</span> 2000;14:1203-1210<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r009&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1097%2F00002030-200006160-00018" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r009&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000087735700018" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r009&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=10894285" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref10"></a><li class="even" id="refItem10"><p class="number">10</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Richman DD</contrib>. Susceptibility to nucleoside analogues of zidovudine-resistant isolates of human immunodeficiency virus. <span class="NLM_source">Am J Med</span> 1990;88:8S-10S<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r010&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1016%2F0002-9343%2890%2990414-9" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r010&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1990DG32900003" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r010&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=2186629" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref11"></a><li class="odd" id="refItem11"><p class="number">11</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Miller V</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Larder BA</contrib>. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure. <span class="NLM_source">Antivir Ther</span> 2001;6:Suppl 3:25-44<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r011&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000171389500003" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r011&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=11678471" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref12"></a><li class="even" id="refItem12"><p class="number">12</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Race E</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Dam E</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Obry V</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Paulous S</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Clavel F</contrib>. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. <span class="NLM_source">AIDS</span> 1999;13:2061-2068<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r012&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1097%2F00002030-199910220-00008" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r012&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000083331200008" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r012&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=10546858" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref13"></a><li class="odd" id="refItem13"><p class="number">13</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Yeni PG</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hammer SM</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Carpenter CC</contrib>, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. <span class="NLM_source">JAMA</span> 2002;288:222-235<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r013&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1001%2Fjama.288.2.222" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r013&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000176711100023" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r013&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=12095387" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref14"></a><li class="even" id="refItem14"><p class="number">14</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Haase AT</contrib>. Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. <span class="NLM_source">Annu Rev Immunol</span> 1999;17:625-656<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r014&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1146%2Fannurev.immunol.17.1.625" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r014&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000080436600020" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r014&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=10358770" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref15"></a><li class="odd" id="refItem15"><p class="number">15</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Ho DD</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Neumann AU</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Perelson AS</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Chen W</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Leonard JM</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Markowitz M</contrib>. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. <span class="NLM_source">Nature</span> 1995;373:123-126<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r015&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1038%2F373123a0" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r015&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1995QB06300049" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r015&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=7816094" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref16"></a><li class="even" id="refItem16"><p class="number">16</p><p class="content">Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-6.<br></p></li><a name="ref17"></a><li class="odd" id="refItem17"><p class="number">17</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Wei X</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Ghosh SK</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Taylor ME</contrib>, et al. Viral dynamics in human immunodeficiency virus type 1 infection. <span class="NLM_source">Nature</span> 1995;373:117-122<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r017&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1038%2F373117a0" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r017&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1995QB06300048" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r017&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=7529365" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref18"></a><li class="even" id="refItem18"><p class="number">18</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Meyerhans A</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Cheynier R</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Albert J</contrib>, et al. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. <span class="NLM_source">Cell</span> 1989;58:901-910<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r018&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1016%2F0092-8674%2889%2990942-2" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r018&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1989AP72200012" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r018&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=2550139" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref19"></a><li class="odd" id="refItem19"><p class="number">19</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Roberts JD</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Bebenek K</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kunkel TA</contrib>. The accuracy of reverse transcriptase from HIV-1. <span class="NLM_source">Science</span> 1988;242:1171-1173<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r019&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1126%2Fscience.2460925" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r019&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1988R005100031" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r019&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=2460925" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref20"></a><li class="even" id="refItem20"><p class="number">20</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Preston BD</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Poiesz BJ</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Loeb LA</contrib>. Fidelity of HIV-1 reverse transcriptase. <span class="NLM_source">Science</span> 1988;242:1168-1171<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r020&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1126%2Fscience.2460924" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r020&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1988R005100030" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r020&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=2460924" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref21"></a><li class="odd" id="refItem21"><p class="number">21</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Coffin JM</contrib>. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. <span class="NLM_source">Science</span> 1995;267:483-489<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r021&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1126%2Fscience.7824947" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r021&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1995QD40300031" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r021&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=7824947" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref22"></a><li class="even" id="refItem22"><p class="number">22</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Gulick RM</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Mellors JW</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Havlir D</contrib>, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. <span class="NLM_source">N Engl J Med</span> 1997;337:734-739<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r022&amp;dbid=20&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1056%2FNEJM199709113371102" onclick="newWindow(this.href);return false">Free Full Text</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r022&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1997XV17400002" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r022&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=9287228" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref23"></a><li class="odd" id="refItem23"><p class="number">23</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hammer SM</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Squires KE</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hughes MD</contrib>, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. <span class="NLM_source">N Engl J Med</span> 1997;337:725-733<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r023&amp;dbid=20&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1056%2FNEJM199709113371101" onclick="newWindow(this.href);return false">Free Full Text</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r023&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1997XV17400001" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r023&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=9287227" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref24"></a><li class="even" id="refItem24"><p class="number">24</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Erice A</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Mayers DL</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Strike DG</contrib>, et al. Primary infection with zidovudine-resistant human immunodeficiency virus type 1. <span class="NLM_source">N Engl J Med</span> 1993;328:1163-1165<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r024&amp;dbid=20&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1056%2FNEJM199304223281605" onclick="newWindow(this.href);return false">Free Full Text</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r024&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1993KY44700005" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r024&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=8455683" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref25"></a><li class="odd" id="refItem25"><p class="number">25</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Witvrouw M</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Pannecouque C</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Van Laethem K</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Desmyter J</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">De Clercq E</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Vandamme AM</contrib>. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. <span class="NLM_source">AIDS</span> 1999;13:1477-1483<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r025&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1097%2F00002030-199908200-00006" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r025&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000082005600006" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r025&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=10465070" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref26"></a><li class="even" id="refItem26"><p class="number">26</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Shafer RW</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Eisen JA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Merigan TC</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Katzenstein DA</contrib>. Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe. <span class="NLM_source">J Virol</span> 1997;71:5441-5448<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r026&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1997XD82900068" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r026&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=9188616" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref27"></a><li class="odd" id="refItem27"><p class="number">27</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Descamps D</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Collin G</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Letourneur F</contrib>, et al. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. <span class="NLM_source">J Virol</span> 1997;71:8893-8898<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r027&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1997YB14300098" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r027&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=9343254" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref28"></a><li class="even" id="refItem28"><p class="number">28</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Palmer S</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Alaeus A</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Albert J</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Cox S</contrib>. Drug susceptibility of subtypes A, B, C, D, and E human immunodeficiency virus type 1 primary isolates. <span class="NLM_source">AIDS Res Hum Retroviruses</span> 1998;14:157-162<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r028&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1089%2Faid.1998.14.157" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r028&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000071619200008" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r028&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=9462926" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref29"></a><li class="odd" id="refItem29"><p class="number">29</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Descamps D</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Apetrei C</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Collin G</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Damond F</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Simon F</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Brun-Vezinet F</contrib>. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors. <span class="NLM_source">AIDS</span> 1998;12:1109-1111<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r029&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000074918500023" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r029&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=9662212" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref30"></a><li class="even" id="refItem30"><p class="number">30</p><p class="content">HIV drug resistance mutations. San Francisco: International AIDS Society-USA, 2002. (Accessed February 9, 2004, at http://www.iasusa.org/resistance_mutations/index.html.)<br></p></li><a name="ref31"></a><li class="odd" id="refItem31"><p class="number">31</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Boucher CA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Cammack N</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Schipper P</contrib>, et al. High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. <span class="NLM_source">Antimicrob Agents Chemother</span> 1993;37:2231-2234<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r031&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1993MA17900031" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r031&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=7504909" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref32"></a><li class="even" id="refItem32"><p class="number">32</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Sarafianos SG</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Das K</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Clark AD Jr</contrib>, et al. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. <span class="NLM_source">Proc Natl Acad Sci U S A</span> 1999;96:10027-10032<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r032&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1073%2Fpnas.96.18.10027" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r032&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000082424100020" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r032&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=10468556" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref33"></a><li class="odd" id="refItem33"><p class="number">33</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Schuurman R</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Nijhuis M</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">van Leeuwen R</contrib>, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). <span class="NLM_source">J Infect Dis</span> 1995;171:1411-1419<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r033&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1093%2Finfdis%2F171.6.1411" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r033&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1995RB29800004" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r033&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=7539472" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref34"></a><li class="even" id="refItem34"><p class="number">34</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Descamps D</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Flandre P</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Calvez V</contrib>, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. <span class="NLM_source">JAMA</span> 2000;283:205-211[Erratum, JAMA 2000;284:1518.]<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r034&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1001%2Fjama.283.2.205" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r034&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000084661400026" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r034&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=10634336" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref35"></a><li class="odd" id="refItem35"><p class="number">35</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Havlir DV</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hellmann NS</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Petropoulos CJ</contrib>, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. <span class="NLM_source">JAMA</span> 2000;283:229-234<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r035&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1001%2Fjama.283.2.229" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r035&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000084661400029" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r035&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=10634339" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref36"></a><li class="even" id="refItem36"><p class="number">36</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Iversen AK</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Shafer RW</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Wehrly K</contrib>, et al. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. <span class="NLM_source">J Virol</span> 1996;70:1086-1090<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r036&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1996TP52600049" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r036&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=8551567" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref37"></a><li class="odd" id="refItem37"><p class="number">37</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kosalaraksa P</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kavlick MF</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Maroun V</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Le R</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Mitsuya H</contrib>. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay. <span class="NLM_source">J Virol</span> 1999;73:5356-5363<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r037&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000080813500013" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r037&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=10364282" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref38"></a><li class="even" id="refItem38"><p class="number">38</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Larder BA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kemp SD</contrib>. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). <span class="NLM_source">Science</span> 1989;246:1155-1158<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r038&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1126%2Fscience.2479983" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r038&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1989CB77200035" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r038&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=2479983" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref39"></a><li class="odd" id="refItem39"><p class="number">39</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Coakley EP</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Gillis JM</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hammer SM</contrib>. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. <span class="NLM_source">AIDS</span> 2000;14:F9-F15<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r039&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1097%2F00002030-200001280-00002" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r039&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000085471600002" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r039&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=10708277" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref40"></a><li class="even" id="refItem40"><p class="number">40</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Shafer RW</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Winters MA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Jellinger RM</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Merigan TC</contrib>. Zidovudine resistance reverse transcriptase mutations during didanosine monotherapy. <span class="NLM_source">J Infect Dis</span> 1996;174:448-449<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r040&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1093%2Finfdis%2F174.2.448" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r040&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1996UZ09300041" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r040&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=8699089" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref41"></a><li class="odd" id="refItem41"><p class="number">41</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Picard V</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Angelini E</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Maillard A</contrib>, et al. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine. <span class="NLM_source">J Infect Dis</span> 2001;184:781-784<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r041&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1086%2F323088" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r041&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000170992000016" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r041&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=11517441" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref42"></a><li class="even" id="refItem42"><p class="number">42</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Boucher CA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">O'Sullivan E</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Mulder JW</contrib>, et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. <span class="NLM_source">J Infect Dis</span> 1992;165:105-110<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r042&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1093%2Finfdis%2F165.1.105" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r042&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1992GW58200014" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r042&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=1370174" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref43"></a><li class="odd" id="refItem43"><p class="number">43</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Meyer PR</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Matsuura SE</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Mian AM</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">So AG</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Scott WA</contrib>. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. <span class="NLM_source">Mol Cell</span> 1999;4:35-43<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r043&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1016%2FS1097-2765%2800%2980185-9" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r043&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000081669300004" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r043&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=10445025" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref44"></a><li class="even" id="refItem44"><p class="number">44</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Arion D</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kaushik N</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">McCormick S</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Borkow G</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Parniak MA</contrib>. Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. <span class="NLM_source">Biochemistry</span> 1998;37:15908-15917<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r044&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1021%2Fbi981200e" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r044&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000077143600034" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r044&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=9843396" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref45"></a><li class="odd" id="refItem45"><p class="number">45</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Boyer PL</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Sarafianos SG</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Arnold E</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hughes SH</contrib>. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. <span class="NLM_source">J Virol</span> 2001;75:4832-4842<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r045&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1128%2FJVI.75.10.4832-4842.2001" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r045&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000168309300039" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r045&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=11312355" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref46"></a><li class="even" id="refItem46"><p class="number">46</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Chamberlain PP</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Ren J</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Nichols CE</contrib>, et al. Crystal structures of zidovudine- or lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184, and 215. <span class="NLM_source">J Virol</span> 2002;76:10015-10019<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r046&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1128%2FJVI.76.19.10015-10019.2002" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r046&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000177849100043" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r046&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=12208978" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref47"></a><li class="odd" id="refItem47"><p class="number">47</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Larder BA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kemp SD</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Harrigan PR</contrib>. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. <span class="NLM_source">Science</span> 1995;269:696-699<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r047&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1126%2Fscience.7542804" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r047&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1995RM70200036" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r047&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=7542804" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref48"></a><li class="even" id="refItem48"><p class="number">48</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Esnouf RM</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Ren J</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hopkins AL</contrib>, et al. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. <span class="NLM_source">Proc Natl Acad Sci U S A</span> 1997;94:3984-3989<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r048&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1073%2Fpnas.94.8.3984" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r048&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1997WW81000092" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r048&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=9108091" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref49"></a><li class="odd" id="refItem49"><p class="number">49</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Richman DD</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Havlir D</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Corbeil J</contrib>, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. <span class="NLM_source">J Virol</span> 1994;68:1660-1666<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r049&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1994MY59600046" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r049&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=7509000" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref50"></a><li class="even" id="refItem50"><p class="number">50</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Bacheler LT</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Anton ED</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kudish P</contrib>, et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. <span class="NLM_source">Antimicrob Agents Chemother</span> 2000;44:2475-2484<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r050&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1128%2FAAC.44.9.2475-2484.2000" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r050&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000088830900038" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r050&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=10952598" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref51"></a><li class="odd" id="refItem51"><p class="number">51</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Boyer PL</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Currens MJ</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">McMahon JB</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Boyd MR</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hughes SH</contrib>. Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. <span class="NLM_source">J Virol</span> 1993;67:2412-2420<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r051&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1993KT98000082" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r051&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=7680393" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref52"></a><li class="even" id="refItem52"><p class="number">52</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Ren J</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Nichols C</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Bird L</contrib>, et al. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. <span class="NLM_source">J Mol Biol</span> 2001;312:795-805<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r052&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1006%2Fjmbi.2001.4988" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r052&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000171536600019" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r052&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=11575933" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref53"></a><li class="odd" id="refItem53"><p class="number">53</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hsiou Y</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Ding J</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Das K</contrib>, et al. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. <span class="NLM_source">J Mol Biol</span> 2001;309:437-445<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r053&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1006%2Fjmbi.2001.4648" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r053&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000169266700008" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r053&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=11371163" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref54"></a><li class="even" id="refItem54"><p class="number">54</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Roberts NA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Martin JA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kinchington D</contrib>, et al. Rational design of peptide-based HIV proteinase inhibitors. <span class="NLM_source">Science</span> 1990;248:358-361<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r054&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1126%2Fscience.2183354" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r054&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1990CZ83700036" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r054&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=2183354" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref55"></a><li class="odd" id="refItem55"><p class="number">55</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Erickson J</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kempf D</contrib>. Structure-based design of symmetric inhibitors of HIV-1 protease. <span class="NLM_source">Arch Virol Suppl</span> 1994;9:19-29<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r055&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=8032250" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref56"></a><li class="even" id="refItem56"><p class="number">56</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Condra JH</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Schleif WA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Blahy OM</contrib>, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. <span class="NLM_source">Nature</span> 1995;374:569-571<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r056&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1038%2F374569a0" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r056&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1995QR06900060" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r056&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=7700387" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref57"></a><li class="odd" id="refItem57"><p class="number">57</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kaplan AH</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Michael SF</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Wehbie RS</contrib>, et al. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. <span class="NLM_source">Proc Natl Acad Sci U S A</span> 1994;91:5597-5601<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r057&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1073%2Fpnas.91.12.5597" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r057&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1994NR27500079" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r057&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=8202533" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref58"></a><li class="even" id="refItem58"><p class="number">58</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Molla A</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Korneyeva M</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Gao Q</contrib>, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. <span class="NLM_source">Nat Med</span> 1996;2:760-766<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r058&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1038%2Fnm0796-760" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r058&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1996UU68000031" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r058&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=8673921" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref59"></a><li class="odd" id="refItem59"><p class="number">59</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Chen Z</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Li Y</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Schock HB</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hall D</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Chen E</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kuo LC</contrib>. Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials. <span class="NLM_source">J Biol Chem</span> 1995;270:21433-21436<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r059&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1074%2Fjbc.270.37.21433" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r059&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1995RU75700002" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r059&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=7665551" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref60"></a><li class="even" id="refItem60"><p class="number">60</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Ridky TW</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kikonyogo A</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Leis J</contrib>, et al. Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate. <span class="NLM_source">Biochemistry</span> 1998;37:13835-13845<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r060&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1021%2Fbi980612k" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r060&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000076367900045" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r060&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=9753473" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref61"></a><li class="odd" id="refItem61"><p class="number">61</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hong L</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Zhang XC</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hartsuck JA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Tang J</contrib>. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance. <span class="NLM_source">Protein Sci</span> 2000;9:1898-1904<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r061&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1110%2Fps.9.10.1898" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r061&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000165328800006" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r061&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=11106162" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref62"></a><li class="even" id="refItem62"><p class="number">62</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Prabu-Jeyabalan M</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">King N</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Nalivaika E</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Scott W</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Schiffer C</contrib>. Drug resistance and substrate recognition in HIV-1 protease. <span class="NLM_source">Antiviral Ther</span> 2002;7:Suppl 1:S36-S36 abstract.<br></p></li><a name="ref63"></a><li class="odd" id="refItem63"><p class="number">63</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Schapiro JM</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Winters MA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Lawrence J</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Merigan TC</contrib>. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. <span class="NLM_source">AIDS</span> 1999;13:359-365<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r063&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1097%2F00002030-199902250-00008" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r063&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000079196000008" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r063&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=10199226" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref64"></a><li class="even" id="refItem64"><p class="number">64</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Doyon L</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Croteau G</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Thibeault D</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Poulin F</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Pilote L</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Lamarre D</contrib>. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. <span class="NLM_source">J Virol</span> 1996;70:3763-3769<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r064&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1996UL10400050" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r064&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=8648711" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref65"></a><li class="odd" id="refItem65"><p class="number">65</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Mammano F</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Petit C</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Clavel F</contrib>. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. <span class="NLM_source">J Virol</span> 1998;72:7632-7637<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r065&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000075328600079" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r065&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=9696866" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref66"></a><li class="even" id="refItem66"><p class="number">66</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Zhang Y</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Imamichi H</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Imamichi T</contrib>, et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. <span class="NLM_source">J Virol</span> 1997;71:6662-6670<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r066&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1997XQ79900046" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r066&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=9261388" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref67"></a><li class="odd" id="refItem67"><p class="number">67</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kilby JM</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Eron JJ</contrib>. Novel therapies based on mechanisms of HIV-1 cell entry. <span class="NLM_source">N Engl J Med</span> 2003;348:2228-2238<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r067&amp;dbid=20&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1056%2FNEJMra022812" onclick="newWindow(this.href);return false">Full Text</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r067&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000183134700010" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r067&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=12773651" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref68"></a><li class="even" id="refItem68"><p class="number">68</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Rimsky LT</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Shugars DC</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Matthews TJ</contrib>. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. <span class="NLM_source">J Virol</span> 1998;72:986-993<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r068&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000071440200012" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r068&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=9444991" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref69"></a><li class="odd" id="refItem69"><p class="number">69</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Wei X</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Decker JM</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Liu H</contrib>, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. <span class="NLM_source">Antimicrob Agents Chemother</span> 2002;46:1896-1905<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r069&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1128%2FAAC.46.6.1896-1905.2002" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r069&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000175662800041" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r069&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=12019106" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref70"></a><li class="even" id="refItem70"><p class="number">70</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Derdeyn CA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Decker JM</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Sfakianos JN</contrib>, et al. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. <span class="NLM_source">J Virol</span> 2001;75:8605-8614<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r070&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1128%2FJVI.75.18.8605-8614.2001" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r070&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000170512800027" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r070&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=11507206" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref71"></a><li class="odd" id="refItem71"><p class="number">71</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Reeves JD</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Gallo SA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Ahmad N</contrib>, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. <span class="NLM_source">Proc Natl Acad Sci U S A</span> 2002;99:16249-16254<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r071&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1073%2Fpnas.252469399" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r071&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000179783400077" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r071&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=12444251" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref72"></a><li class="even" id="refItem72"><p class="number">72</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Labrosse B</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Labernardiere JL</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Dam E</contrib>, et al. Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors. <span class="NLM_source">J Virol</span> 2003;77:1610-1613<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r072&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1128%2FJVI.77.2.1610-1613.2003" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r072&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000180166600081" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r072&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=12502877" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref73"></a><li class="odd" id="refItem73"><p class="number">73</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Dulioust A</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Paulous S</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Guillemot L</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Delavalle AM</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Boue F</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Clavel F</contrib>. Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors. <span class="NLM_source">J Virol</span> 1999;73:850-854<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r073&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000077461700102" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r073&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=9847401" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref74"></a><li class="even" id="refItem74"><p class="number">74</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Droz C</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Morand-Joubert L</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Raguin G</contrib>, et al. Impact and evolution of resistance in patients treated by a salvage regimen combining amprenavir, lopinavir and ritonavir (the puzzle1 study). <span class="NLM_source">Antiviral Ther</span> 2002;7:Suppl 1:S111-S111 abstract.<br></p></li><a name="ref75"></a><li class="odd" id="refItem75"><p class="number">75</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Barbour JD</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Wrin T</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Grant RM</contrib>, et al. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. <span class="NLM_source">J Virol</span> 2002;76:11104-11112<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r075&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1128%2FJVI.76.21.11104-11112.2002" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r075&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000178512300053" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r075&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=12368352" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref76"></a><li class="even" id="refItem76"><p class="number">76</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Ross L</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Johnson M</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">DeMasi R</contrib>, et al. Viral genetic heterogeneity in HIV-1-infected individuals is associated with increasing use of HAART and higher viremia. <span class="NLM_source">AIDS</span> 2000;14:813-819<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r076&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1097%2F00002030-200005050-00007" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r076&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000086969100007" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r076&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=10839589" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref77"></a><li class="odd" id="refItem77"><p class="number">77</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hanna GJ</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Johnson VA</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kuritzkes DR</contrib>, et al. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. <span class="NLM_source">J Infect Dis</span> 2000;181:904-911<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r077&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1086%2F315329" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r077&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000086344400013" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r077&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=10720511" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref78"></a><li class="even" id="refItem78"><p class="number">78</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Mammano F</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Trouplin V</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Zennou V</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Clavel F</contrib>. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. <span class="NLM_source">J Virol</span> 2000;74:8524-8531<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r078&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1128%2FJVI.74.18.8524-8531.2000" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r078&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000088933700036" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r078&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=10954553" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref79"></a><li class="odd" id="refItem79"><p class="number">79</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Nijhuis M</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Schuurman R</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">de Jong D</contrib>, et al. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. <span class="NLM_source">AIDS</span> 1999;13:2349-2359<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r079&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1097%2F00002030-199912030-00006" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r079&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000084007200006" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r079&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=10597776" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref80"></a><li class="even" id="refItem80"><p class="number">80</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Croteau G</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Doyon L</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Thibeault D</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">McKercher G</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Pilote L</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Lamarre D</contrib>. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. <span class="NLM_source">J Virol</span> 1997;71:1089-1096<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r080&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1997WC30500029" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r080&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=8995629" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref81"></a><li class="odd" id="refItem81"><p class="number">81</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Martinez-Picado J</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Savara AV</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Sutton L</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">D'Aquila RT</contrib>. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. <span class="NLM_source">J Virol</span> 1999;73:3744-3752<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r081&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000079701100030" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r081&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=10196268" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref82"></a><li class="even" id="refItem82"><p class="number">82</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Zennou V</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Mammano F</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Paulous S</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Mathez D</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Clavel F</contrib>. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. <span class="NLM_source">J Virol</span> 1998;72:3300-3306<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r082&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000072586900086" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r082&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=9525657" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref83"></a><li class="odd" id="refItem83"><p class="number">83</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Back NK</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Nijhuis M</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Keulen W</contrib>, et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. <span class="NLM_source">EMBO J</span> 1996;15:4040-4049<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r083&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1996VC66700028" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r083&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=8670908" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref84"></a><li class="even" id="refItem84"><p class="number">84</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Bleiber G</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Munoz M</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Ciuffi A</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Meylan P</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Telenti A</contrib>. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1. <span class="NLM_source">J Virol</span> 2001;75:3291-3300<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r084&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1128%2FJVI.75.7.3291-3300.2001" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r084&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000167469600024" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r084&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=11238855" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref85"></a><li class="odd" id="refItem85"><p class="number">85</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Deeks SG</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Wrin T</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Liegler T</contrib>, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. <span class="NLM_source">N Engl J Med</span> 2001;344:472-480<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r085&amp;dbid=20&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1056%2FNEJM200102153440702" onclick="newWindow(this.href);return false">Free Full Text</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r085&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000166922100002" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r085&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=11172188" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref86"></a><li class="even" id="refItem86"><p class="number">86</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kaufmann D</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Pantaleo G</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Sudre P</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Telenti A</contrib>. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART): Swiss HIV Cohort Study. <span class="NLM_source">Lancet</span> 1998;351:723-724<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r086&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1016%2FS0140-6736%2898%2924010-4" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r086&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000072463800012" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r086&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=9504519" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref87"></a><li class="odd" id="refItem87"><p class="number">87</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Piketty C</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Castiel P</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Belec L</contrib>, et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. <span class="NLM_source">AIDS</span> 1998;12:745-750<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r087&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1097%2F00002030-199807000-00011" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r087&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000073548000011" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r087&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=9619806" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref88"></a><li class="even" id="refItem88"><p class="number">88</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Deeks SG</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Barbour JD</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Martin JN</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Swanson MS</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Grant RM</contrib>. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. <span class="NLM_source">J Infect Dis</span> 2000;181:946-953<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r088&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1086%2F315334" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r088&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000086344400019" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r088&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=10720517" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref89"></a><li class="odd" id="refItem89"><p class="number">89</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Resch W</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Parkin N</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Stuelke EL</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Watkins T</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Swanstrom R</contrib>. A multiple-site-specific heteroduplex tracking assay as a tool for the study of viral population dynamics. <span class="NLM_source">Proc Natl Acad Sci U S A</span> 2001;98:176-181<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r089&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1073%2Fpnas.011511298" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r089&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000166222600036" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r089&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=11120887" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref90"></a><li class="even" id="refItem90"><p class="number">90</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hance AJ</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Lemiale V</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Izopet J</contrib>, et al. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. <span class="NLM_source">J Virol</span> 2001;75:6410-6417<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r090&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1128%2FJVI.75.14.6410-6417.2001" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r090&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000169454200019" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r090&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=11413308" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref91"></a><li class="odd" id="refItem91"><p class="number">91</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Charpentier C</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Dwyer D</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Lecossier D</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Clavel F</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hance A</contrib>. Co-evolution and competition of viral populations with distinct resistance genotypes in patients failing treatment with protease inhibitors. <span class="NLM_source">Antiviral Ther</span> 2002;7:Suppl 1:S42-S42 abstract.<br></p></li><a name="ref92"></a><li class="even" id="refItem92"><p class="number">92</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Finzi D</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hermankova M</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Pierson T</contrib>, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. <span class="NLM_source">Science</span> 1997;278:1295-1300<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r092&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1126%2Fscience.278.5341.1295" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r092&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1997YG04300046" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r092&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=9360927" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref93"></a><li class="odd" id="refItem93"><p class="number">93</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Wong JK</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hezareh M</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Gunthard HF</contrib>, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. <span class="NLM_source">Science</span> 1997;278:1291-1295<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r093&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1126%2Fscience.278.5341.1291" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r093&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=A1997YG04300045" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r093&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=9360926" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref94"></a><li class="even" id="refItem94"><p class="number">94</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Izopet J</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Souyris C</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hance A</contrib>, et al. Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype. <span class="NLM_source">J Infect Dis</span> 2002;185:1506-1510<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r094&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1086%2F340215" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r094&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000175314700018" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r094&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=11992288" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref95"></a><li class="odd" id="refItem95"><p class="number">95</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Verhofstede C</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Wanzeele FV</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Van Der Gucht B</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">De Cabooter N</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Plum J</contrib>. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. <span class="NLM_source">AIDS</span> 1999;13:2541-2546<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r095&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1097%2F00002030-199912240-00007" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r095&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000084541200007" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r095&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=10630523" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref96"></a><li class="even" id="refItem96"><p class="number">96</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Dybul M</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Fauci AS</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Bartlett JG</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kaplan JE</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Pau AK</contrib>. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents: recommendations of the Panel on Clinical Practices for Treatment of HIV. <span class="NLM_source">MMWR Recomm Rep</span> 2002;51:1-55<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r096&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=12027060" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref97"></a><li class="odd" id="refItem97"><p class="number">97</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hirsch MS</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Brun-Vezinet F</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Clotet B</contrib>, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. <span class="NLM_source">Clin Infect Dis</span> 2003;37:113-128<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r097&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1086%2F375597" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r097&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000183826700016" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r097&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=12830416" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref98"></a><li class="even" id="refItem98"><p class="number">98</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Haubrich R</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Demeter L</contrib>. International perspectives on antiretroviral resistance: clinical utility of resistance testing: retrospective and prospective data supporting use and current recommendations. <span class="NLM_source">J Acquir Immune Defic Syndr</span> 2001;26:Suppl 1:S51-S59<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r098&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1097%2F00042560-200103011-00006" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r098&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000167554300006" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r098&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=11265001" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref99"></a><li class="odd" id="refItem99"><p class="number">99</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hazuda DJ</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Felock P</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Witmer M</contrib>, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. <span class="NLM_source">Science</span> 2000;287:646-650<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r099&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1126%2Fscience.287.5453.646" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r099&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000084989400046" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r099&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=10649997" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref100"></a><li class="lastChild even" id="refItem100"><p class="number">100</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Trkola A</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kuhmann SE</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Strizki JM</contrib>, et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. <span class="NLM_source">Proc Natl Acad Sci U S A</span> 2002;99:395-400<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r100&amp;dbid=16&amp;doi=10.1056%2FNEJMra025195&amp;key=10.1073%2Fpnas.012519099" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r100&amp;dbid=128&amp;doi=10.1056%2FNEJMra025195&amp;key=000173233300071" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r100&amp;dbid=8&amp;doi=10.1056%2FNEJMra025195&amp;key=11782552" onclick="newWindow(this.href);return false">Medline</a></p></li></ol></div></dd><dd style="display: none;" id="citedby"><div class="section"><h3>Citing Articles</h3><ol class="striped"><li class="firstChild odd"><p class="number">1</p><p class="content">Leandro R. Jones, Franco Moretti, Andrea Y. Calvo, Darío A. Dilernia, Julieta M. Manrique, Manuel Gómez-Carrillo, Horacio Salomón.  (2012) Drug Resistance Mutations in HIV
              <i>pol</i>
              Sequences from Argentinean Patients Under Antiretroviral Treatment: Subtype, Gender, and Age Issues. <i><span class="NLM_source">AIDS Research and Human Retroviruses</span></i> <b>28</b>:8, 949-955<br><span class="CbLinks"><!--noindex--><a class="ref" href="http://dx.doi.org.libgate.library.nuigalway.ie/10.1089/aid.2011.0287" target="_top" title="Opens new window"> CrossRef </a><!--/noindex--></span></p></li><li class="even"><p class="number">2</p><p class="content">The Strategies for Management of Antiretroviral Therapy (SMART) Study Group.  (2006) CD4+ Count–Guided Interruption of Antiretroviral Treatment. <i><span class="NLM_source">New England Journal of Medicine</span></i> <b>355</b>:22, 2283-2296<br><span class="CbLinks"><a class="ref nowrap" href="http://www.nejm.org.libgate.library.nuigalway.ie/doi/full/10.1056/NEJMoa062360">Free Full Text</a><!-- ${xml_link: 10.1056%2FNEJMoa062360} --></span></p></li><li class="odd"><p class="number">3</p><p class="content"> (2004) Nevirapine plus Zidovudine to Prevent Mother-to-Child Transmission of HIV. <i><span class="NLM_source">New England Journal of Medicine</span></i> <b>351</b>:19, 2013-2015<br><span class="CbLinks"><a class="ref nowrap" href="http://www.nejm.org.libgate.library.nuigalway.ie/doi/full/10.1056/NEJM200411043511918">Free Full Text</a><!-- ${xml_link: 10.1056%2FNEJM200411043511918} --></span></p></li><li class="lastChild even"><p class="number">4</p><p class="content"> Calmy ,  Alexandra ,  Pascual ,  Fernando , ,  Ford ,  Nathan , .  (2004) HIV Drug Resistance. <i><span class="NLM_source">New England Journal of Medicine</span></i> <b>350</b>:26, 2720-2721<br><span class="CbLinks"><a class="ref nowrap" href="http://www.nejm.org.libgate.library.nuigalway.ie/doi/full/10.1056/NEJM200406243502621">Free Full Text</a><!-- ${xml_link: 10.1056%2FNEJM200406243502621} --></span></p></li></ol></div></dd><dd style="display: none;" class="lastChild" id="letters"><div class="letterContent" rel="10.1056/NEJMra025195"><a name="articleTop" rel="10.1056/NEJM200406243502621"></a><h1>HIV Drug Resistance</h1><p class="citationLine"><span class="citation">N Engl J Med 2004;  350:2720-2721</span><a href="http://www.nejm.org.libgate.library.nuigalway.ie/toc/nejm/350/26/">June 24, 2004</a><span class="doi">DOI:  10.1056/NEJM200406243502621</span></p><dl class="articleTabs tabPanel"><dt class="active article" id="articleTab">Article</dt><dd id="article"><div class="letter"><h3>To the Editor:</h3><p>  Clavel and Hance (March 4 issue)<span class="ref"><a href="#ref1" class="showRefLayer" rel="#refLayer">1</a></span> review resistance to drugs used for the treatment of human immunodeficiency virus infection. Few data are available concerning patterns of antiretroviral-drug resistance among patients in developing countries. However, the fact that the expected virologic success rates of commonly used regimens containing nucleoside reverse-transcriptase inhibitors is approximately 65 percent at 48 weeks is cause for alarm.<span class="ref"><a href="#ref2" class="showRefLayer" rel="#refLayer">2</a></span> </p><p>Access to second-line regimens is restricted by their cost, which is currently 10 to 20 times that of first-line regimens. For example, the second-line regimen of tenofovir, didanosine, and either ritonavir or lopinavir, recommended by the World Health Organization, costs up to $6,000 (U.S. dollars) per patient per year.<span class="ref"><a href="#ref3" class="showRefLayer" rel="#refLayer">3,4</a></span> In the past four years, generic competition has brought the price of first-line drugs down from $10,000 to less than $300 (U.S. dollars) per person per year.<span class="ref"><a href="#ref5" class="showRefLayer" rel="#refLayer">5</a></span> A similar market situation must be encouraged for second-line medicines.</p><p>Moreover, the diagnosis of virologic failure (based on clinical data or the CD4 cell count) is often delayed owing to a lack of affordable and easy-to-use viral-load monitoring. New tools must also be developed to diagnose early virologic failure to control viral replication more efficiently, to improve the clinical outcome, and to prevent the development of resistance to second-line medicines.</p><div class="section section-hr"></div><div class="section section-back"><div class="section"><p>Alexandra Calmy, M.D.<br>Fernando Pascual, Pharm.D.<br>Doctors without Borders, 1211 Geneva, Switzerland  <br><a class="email" href="mailto:alexandra.calmy@geneva.msf.org"><span class="nobrWithWbr">alexandra.<wbr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">calmy@geneva.<wbr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">msf.<wbr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">org</span></a></p><p>Nathan Ford, B.Sc.<br>Doctors without Borders, London EC1N 8QX, United Kingdom<br></p></div></div><div class="section section-back"></div><span class="moreLink"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/doi/full/10.1056/toggleRef" class="toggleRef">5 References</a></span><div class="letterReferences hidden"><div class="section"><ol class="striped"><a name="ref1"></a><li class="odd" id="refItem1"><p class="number">1</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Clavel F</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Hance AJ</contrib>. HIV drug resistance. <span class="NLM_source">N Engl J Med</span> 2004;350:1023-1035<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r001&amp;dbid=20&amp;doi=10.1056%2FNEJM200406243502621&amp;key=10.1056%2FNEJMra025195" onclick="newWindow(this.href);return false">Full Text</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r001&amp;dbid=128&amp;doi=10.1056%2FNEJM200406243502621&amp;key=000189363600010" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r001&amp;dbid=8&amp;doi=10.1056%2FNEJM200406243502621&amp;key=14999114" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref2"></a><li class="even" id="refItem2"><p class="number">2</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Van Leth F</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Phanuphak P</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Ruxrungtham K</contrib>, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. <span class="NLM_source">Lancet</span> 2004;363:1253-1263<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r002&amp;dbid=16&amp;doi=10.1056%2FNEJM200406243502621&amp;key=10.1016%2FS0140-6736%2804%2915997-7" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r002&amp;dbid=128&amp;doi=10.1056%2FNEJM200406243502621&amp;key=000220904900006" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r002&amp;dbid=8&amp;doi=10.1056%2FNEJM200406243502621&amp;key=15094269" onclick="newWindow(this.href);return false">Medline</a></p></li><a name="ref3"></a><li class="odd" id="refItem3"><p class="number">3</p><p class="content">Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach. Geneva: World Health Organization, December 2003.<br></p></li><a name="ref4"></a><li class="even" id="refItem4"><p class="number">4</p><p class="content">Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries. 5th ed. Geneva: Médecins Sans Frontières, December 2003.<br></p></li><a name="ref5"></a><li class="odd" id="refItem5"><p class="number">5</p><p class="content"><contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">von Schoen Angerer T</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Wilson D</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Ford N</contrib>, <contrib xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" contrib-type="author">Kasper T</contrib>. Access and activism: the ethics of providing antiretroviral therapy in developing countries. <span class="NLM_source">AIDS</span> 2001;15:Suppl 5:S81-S90<br><a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r005&amp;dbid=16&amp;doi=10.1056%2FNEJM200406243502621&amp;key=10.1097%2F00002030-200100005-00011" onclick="newWindow(this.href);return false">CrossRef</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r005&amp;dbid=128&amp;doi=10.1056%2FNEJM200406243502621&amp;key=000172834100011" onclick="newWindow(this.href);return false">Web of Science</a> | <a href="http://www.nejm.org.libgate.library.nuigalway.ie/servlet/linkout?suffix=r005&amp;dbid=8&amp;doi=10.1056%2FNEJM200406243502621&amp;key=11816178" onclick="newWindow(this.href);return false">Medline</a></p></li></ol></div></div></div></dd><!--DiscussionReplacer_Tab_--></dl></div></dd></dl>
    





    


</div>


        
        





<div id="rightRail" class="">
    <!-- omit the institutional logo from the following pages -->
    
            
            <div id="institutionBox">
                
                <p>Access Provided By:<br><span class="institutionName">National University Ireland Galway  - IREL</span></p>
                
                <div style="clear: both;"></div>
            </div>
            
        
    
                        











<!-- toolsContainer -->
<div id="toolsContainer">
	<!-- toolsBox -->
	<div id="toolsBox">
		<h3>Tools</h3>
		<ul class="firstGroup">
			
			<li class="downloadPDF firstChild">
				<a href="http://www.nejm.org.libgate.library.nuigalway.ie/doi/pdf/10.1056/NEJMra025195" class="zone-tools-articlePdf">

					
					PDF
				</a>
			</li>
			
			
			<li class="printPage">
				<a href="http://www.nejm.org.libgate.library.nuigalway.ie/doi/full/10.1056/NEJMra025195" class="viewType-Print viewClass-Print zone-tools-articlePrint">

					
					Print
				</a>
			</li>
			
			<li class="downloadCitation lastChild">
				<a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showCitFormats?doi=10.1056%2FNEJMra025195" class="viewType-Layer viewClass-MediumLayer zone-tools-downloadCitation event-layer-downloadCitation-open">

					
					Download Citation
				</a>
			</li>
			
			
			
			
			
            
		</ul>
		<ul class="secondGroup">
			<li class="emailPage firstChild">
				<a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/showMailPage?href=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;title=HIV+Drug+Resistance&amp;doi=10.1056%2FNEJMra025195" class="viewType-Layer viewClass-MediumLayer zone-tools-articleEmail">

					
					
					
					E-Mail
				</a>
			</li>
			
			<li class="savePage">
				<a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/addTag?uactid=savePage&amp;uacturi=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;doi=10.1056%2FNEJMra025195" id="savePage" class="viewType-Layer viewClass-MediumLayer zone-tools-articleSave">

					
						
						
					
					Save
				</a>
			</li>
			
			<li class="getAlert">
				<a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/addCitationAlert?context=add&amp;uactid=getAlert&amp;uacturi=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;doi=10.1056%2FNEJMra025195" id="getAlert" class="viewType-Layer viewClass-MediumLayer zone-tools-articleEmailAlert">

					
					
						
						
					
					Article Alert
				</a>
			</li>
			
			
			
			
			<li class="reprints"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/page/about-nejm/reprints" class="zone-tools-reprints">Reprints</a></li>
            <li class="permissions"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/doi/full/10.1056/https%3A%2F%2Fs100.copyright.com%2FAppDispatchServlet%3Fauthor%3DFran%25C3%25A7ois%2BClavel%252C%2BAllan%2BJ.%2BHance%26contentID%3D10.1056%252FNEJMra025195%26issueNum%3D10%26orderBeanReset%3Dtrue%26publication%3Dnejm%26publicationDate%3D03%252F04%252F2004%26publisherName%3Dmassmed%26title%3DHIV%2BDrug%2BResistance%26volumeNum%3D350" class="zone-tools-permissions">Permissions</a></li>
			<li class="addThisIcon lastChild"><a href="http://www.addthis.com/bookmark.php" class="addthis_button zone-tools-share-click" target="_top">Share/Bookmark</a></li>
		</ul>
	</div>
	<!-- /toolsBox -->
	<!-- toolsAd -->
	<div class="toolsAd">
		

<div class="bottomAd">
    
    <div class="ad">
        














<div id="CM8ShowAd1369757135993" title="MicroTools" class="MicroTools CM8">
<noscript><a href="http://web.checkm8.com/adam/ep/click/mms.nej.articles/MicroTools"><img src="http://web.checkm8.com/adam/noscript?cat=mms.nej.articles&amp;page=1369757135993&amp;format=MicroTools" border="0" alt="Advertisement" /></a></noscript>

</div>
    </div>
</div>
	</div>
	<!-- /toolsAd -->
</div>
<!-- /toolsContainer -->

                    
                









<div id="related"><div id="relatedContent"><h3>Related Articles</h3><ul><li class="firstChild lastChild"><p class="articleType"><pub-title xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" title-type="toc-heading-title" title-length="standard" title-usage="default" translit-method="none" is-translated="false" media-type="text-xml" source="default" xml:lang="EN">Correspondence</pub-title></p><p class="articleLink"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/doi/full/10.1056/NEJM200406243502621">HIV Drug Resistance</a></p><p class="articleDate">June 24, 2004 | A. Calmy and Others</p></li></ul></div><div id="moreIn" class="wide"><h3>More In</h3><ul><li class="firstChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/browse?category=review">Review</a></li><li class="lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/toc/nejm/350/10/">March 4, 2004</a></li></ul></div></div>

                
                    
                
        
                


<div id="rightRailAd">
<div class="bannerAdTower">
<div class="rightTower">















<div id="CM8ShowAd1369757135994" title="MedRectangle" class="MedRectangle CM8">
<noscript><a href="http://web.checkm8.com/adam/ep/click/mms.nej.articles/MedRectangle"><img src="http://web.checkm8.com/adam/noscript?cat=mms.nej.articles&amp;page=1369757135994&amp;format=MedRectangle" border="0" alt="Advertisement" /></a></noscript>

</div>
</div>
</div>
</div>
                



















<div id="trendsMod" class="mod pad">
    <div class="modHead">
        <h3>Trends</h3>
        
                <h4>Most Viewed (Last Week)</h4>
            
    </div>
    <div class="modBody">
        
        <ul class="csf">
            
            <li class="firstChild">
                <div class="articleType">Original Article</div>
                <div class="articleLink">
                    <a href="http://www.nejm.org.libgate.library.nuigalway.ie/doi/full/10.1056/NEJMoa1214103">Prone Positioning in Severe Acute Respiratory Distress Syndrome</a>
                </div>

                
                
                        <div class="articleDate">May 20, 2013
                            
                                | C. Guérin and Others
                            
                        </div>
                    


            </li>
            
            <li>
                <div class="articleType">Original Article</div>
                <div class="articleLink">
                    <a href="http://www.nejm.org.libgate.library.nuigalway.ie/doi/full/10.1056/NEJMoa1302854">A Randomized Trial of Nighttime Physician Staffing in an Intensive Care Unit</a>
                </div>

                
                
                        <div class="articleDate">May 20, 2013
                            
                                | M.P. Kerlin and Others
                            
                        </div>
                    


            </li>
            
            <li class="lastChild">
                <div class="articleType">Case Records of the Massachusetts General Hospital</div>
                <div class="articleLink">
                    <a href="http://www.nejm.org.libgate.library.nuigalway.ie/doi/full/10.1056/NEJMcpc1215971">Case Challenge</a>
                </div>

                
                
                        <div class="articleDate">May 22, 2013
                            
                                | null
                            
                        </div>
                    


            </li>
            
        </ul>
    </div>
    <div class="modFoot">
        <p class="moreLink"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/journal-articles">More Trends</a></p>
    </div>
    

<div class="bottomAd">
    
    <div class="ad">
        














<div id="CM8ShowAd1369757136011" title="MicroTrends" class="MicroTrends CM8">
<noscript><a href="http://web.checkm8.com/adam/ep/click/mms.nej.articles/MicroTrends"><img src="http://web.checkm8.com/adam/noscript?cat=mms.nej.articles&amp;page=1369757136011&amp;format=MicroTrends" border="0" alt="Advertisement" /></a></noscript>

</div>
    </div>
</div>
</div>


                
                
                        












<script type="text/javascript" src="untitled"></script><div id="nejm_jobs">  <div style="padding: 0px; margin: 0px; background: none repeat ; 0% rgb(255, 51, 0); clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; vertical-align: baseline; font-weight: normal; float: none; letter-spacing: normal; max-width: none; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 300px; border: 1px solid rgb(255, 51, 0); height: 1px; max-height: 1px; overflow: hidden; line-height: 1px; font-size: 1px;"></div> <!-- top red rectangle --><div id="nejm-widget" style="padding: 0px; margin: 0px; background: none repeat ; 0% rgb(255, 255, 255); clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; vertical-align: baseline; font-weight: normal; float: none; height: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 300px; border-right: 1px solid rgb(207, 207, 207); border-width: medium 1px 1px; border-style: none solid solid; border-color: -moz-use-text-color rgb(207, 207, 207) rgb(207, 207, 207); -moz-border-top-colors: none; -moz-border-right-colors: none; -moz-border-bottom-colors: none; -moz-border-left-colors: none; border-image: none; line-height: 12px; font-size: 14px;"><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; font-weight: normal; float: none; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 10px; font-size: 1px; height: 10px; line-height: 10px;">&nbsp;</div><div style="padding: 0px; margin: 0px 0px 0px 10px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;">	<a target="nejm-win" style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; line-height: 1px; text-decoration: none;" href="http://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" style="background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: inline; margin: 0px; padding: 0px; border: medium none;" src="nejmCCID-JobsWidget.gif">	</a></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; font-weight: normal; float: none; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 10px; font-size: 1px; height: 10px; line-height: 10px;">&nbsp;</div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border-right: medium none; border-left: medium none; -moz-border-top-colors: none; -moz-border-right-colors: none; -moz-border-bottom-colors: none; -moz-border-left-colors: none; border-image: none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 100%; border-width: 1px medium; border-style: solid none; border-color: rgb(207, 207, 207) -moz-use-text-color;"> <!-- content --><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; font-weight: normal; float: none; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 10px; font-size: 1px; height: 10px; line-height: 10px;">&nbsp;</div><div style="padding: 0px; margin: 0px 0px 4px 10px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: 'Times New Roman',Times,serif; font-size: 11px; color: rgb(51, 51, 51); font-weight: bold;">PHYSICIAN JOBS</div><div style="padding: 0px; margin: 0px 0px 0px 10px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Arial; font-size: 10px; color: rgb(102, 102, 102);">May 28, 2013</div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; font-weight: normal; float: none; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 10px; font-size: 1px; height: 8px; line-height: 8px;">&nbsp;</div><div style="padding: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; margin: 0px 10px;"><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><span style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Tahoma; font-size: 9px; color: black; font-weight: bold;">Surgery, Orthopedic</span></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><a target="nejm-job-win" style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Arial; font-size: 11px; color: rgb(0, 104, 146); text-decoration: none;" onmouseover="jlho(this);" onmouseout="jlou(this);" href="http://www.nejmcareercenter.org/job/16990/orthopedic-surgeon/?query=fjwp">ORTHOPEDIC SURGEON</a></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><span style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Arial; font-size: 10px; color: rgb(51, 51, 51); text-transform: uppercase;">Maine</span></div></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; font-weight: normal; float: none; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 10px; font-size: 1px; height: 8px; line-height: 8px;">&nbsp;</div><div style="padding: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; margin: 0px 10px;"><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><span style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Tahoma; font-size: 9px; color: black; font-weight: bold;">Chiefs/Directors/Dept. Heads</span></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><a target="nejm-job-win" style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Arial; font-size: 11px; color: rgb(0, 104, 146); text-decoration: none;" onmouseover="jlho(this);" onmouseout="jlou(this);" href="http://www.nejmcareercenter.org/job/16630/physician-medical-director-compensation-and-pension/?query=fjwp">PHYSICIAN MEDICAL DIRECTOR, COMPENSATION AND PENSION</a></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><span style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Arial; font-size: 10px; color: rgb(51, 51, 51); text-transform: uppercase;">Texas</span></div></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; font-weight: normal; float: none; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 10px; font-size: 1px; height: 8px; line-height: 8px;">&nbsp;</div><div style="padding: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; margin: 0px 10px;"><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><span style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Tahoma; font-size: 9px; color: black; font-weight: bold;">Family Medicine</span></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><a target="nejm-job-win" style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Arial; font-size: 11px; color: rgb(0, 104, 146); text-decoration: none;" onmouseover="jlho(this);" onmouseout="jlou(this);" href="http://www.nejmcareercenter.org/job/16143/family-medicine-nantucket-massachusetts/?query=fjwf">FAMILY MEDICINE, NANTUCKET, MASSACHUSETTS</a></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><span style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Arial; font-size: 10px; color: rgb(51, 51, 51); text-transform: uppercase;">Massachusetts</span></div></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; font-weight: normal; float: none; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 10px; font-size: 1px; height: 8px; line-height: 8px;">&nbsp;</div><div style="padding: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; margin: 0px 10px;"><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><span style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Tahoma; font-size: 9px; color: black; font-weight: bold;">Hospitalist</span></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><a target="nejm-job-win" style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Arial; font-size: 11px; color: rgb(0, 104, 146); text-decoration: none;" onmouseover="jlho(this);" onmouseout="jlou(this);" href="http://www.nejmcareercenter.org/job/16451/hospitalist-connecticut/?query=fjwf">HOSPITALIST, CONNECTICUT</a></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><span style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Arial; font-size: 10px; color: rgb(51, 51, 51); text-transform: uppercase;">Connecticut</span></div></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; font-weight: normal; float: none; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 10px; font-size: 1px; height: 8px; line-height: 8px;">&nbsp;</div><div style="padding: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; margin: 0px 10px;"><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><span style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Tahoma; font-size: 9px; color: black; font-weight: bold;">Psychiatry</span></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><a target="nejm-job-win" style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Arial; font-size: 11px; color: rgb(0, 104, 146); text-decoration: none;" onmouseover="jlho(this);" onmouseout="jlou(this);" href="http://www.nejmcareercenter.org/job/16357/child-adolescent-psychiatrist-intermountain-healthcare-system/?query=fjwf">CHILD/ADOLESCENT PSYCHIATRIST, INTERMOUNTAIN HEALTHCARE SYSTEM</a></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><span style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Arial; font-size: 10px; color: rgb(51, 51, 51); text-transform: uppercase;">Utah</span></div></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; font-weight: normal; float: none; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 10px; font-size: 1px; height: 8px; line-height: 8px;">&nbsp;</div><div style="padding: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; margin: 0px 10px;"><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><span style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Tahoma; font-size: 9px; color: black; font-weight: bold;">Hospitalist</span></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><a target="nejm-job-win" style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Arial; font-size: 11px; color: rgb(0, 104, 146); text-decoration: none;" onmouseover="jlho(this);" onmouseout="jlou(this);" href="http://www.nejmcareercenter.org/job/16868/hospitalist-position/?query=fjws">Hospitalist Position</a></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"><span style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: Arial; font-size: 10px; color: rgb(51, 51, 51); text-transform: uppercase;">Maine</span></div></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; font-weight: normal; float: none; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 10px; font-size: 1px; height: 10px; line-height: 10px;">&nbsp;</div></div> <!-- content --><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block;"> <!-- footer --><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; font-weight: normal; float: none; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 10px; font-size: 1px; height: 5px; line-height: 5px;">&nbsp;</div><div style="padding: 0px; margin: 0px 10px 0px 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; text-align: right;"><a target="nejm-win" style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; float: none; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; font-family: 'Times New Roman',Times,serif; font-size: 13px; color: rgb(255, 51, 0); text-decoration: none; text-align: right;" href="http://www.nejmcareercenter.org/?query=fjw">nejmcareercenter.org</a></div><div style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; border: medium none; vertical-align: baseline; font-weight: normal; float: none; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; width: 10px; font-size: 1px; height: 9px; line-height: 9px;">&nbsp;</div></div> <!-- footer --><img style="padding: 0px; margin: 0px; background: none repeat ; 0% transparent; clear: none; bottom: auto; font-family: Arial,Helvetica,sans-serif; font-style: normal; min-height: 0px; min-width: 0px; font-size: 11px; border: medium none; vertical-align: baseline; line-height: 14px; font-weight: normal; height: auto; width: auto; letter-spacing: normal; max-height: none; max-width: none; overflow: visible; position: static; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; visibility: visible; white-space: normal; z-index: auto; display: block; float: none;" src="__utm.gif" height="1" width="1"></div> <!-- nejm-widget --></div>

                    
                
                



<!-- placeholder id=null, description=N-siteWide-email -->
    <div class="emailAlert"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1132&amp;url=%2Faction%2FcdfProxy%3Faction%3Dcampaign%26promo%3DONFQSU06%26prc%3DONFQSU06%26cpc%3DFMDAALLP0612A%26URL%3Dhttp%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMra025195&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800"><img src="WeeklyTOC_Update.gif"></a>

</div>



	
      		<!-- placeholder id=null, description=N-ad-article-rightRail-1 -->
    			  <a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=5017&amp;url=%2Fpage%2Fglobal-health&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800"><img src="GlobalHealth_GH4World_300x150.jpg"></a>
    		
      	
    
</div>

   




    
<script type="text/javascript">

    $("#cdfRegister").attr("href", $("#cdfRegister").attr('href') + "&url=" + window.location.href);
</script>


</div>



<div id="footer">
    <!-- placeholder id=null, description=N-ad-footer-1 -->
        <div class="rightAd"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=2078&amp;url=%2Fcontinuing-medical-education&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800"><img src="CME_300Exams_175x48.gif"></a></div>
    
    <!-- placeholder id=null, description=N-footer -->
        <dl>
  <dt class="firstChild">Content:</dt>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2F&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800" tabindex="100">Home</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Ftoc%2Fnejm%2Fmedical-journal&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Current Issue</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fmedical-article-index&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Articles</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fmedical-index&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Issue Index</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fmedical-specialties&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Specialties &amp; Topics</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fmultimedia&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Multimedia &amp; Images</a></dd>
  <dd class="lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fmedical-index&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Archive 1812-1989</a></dd>
</dl>
<dl>
  <dt class="firstChild">Information For:</dt>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Faction%2FcdfProxy%3Faction%3DauthorCenter&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Authors</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Faction%2FcdfProxy%3Faction%3DauthorCenter&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Reviewers</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Fproducts-and-services&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Subscribers</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Finstitution%2Fresource-center&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Institutions</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fmedia&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Media</a></dd>
  <dd class="lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Fhow-to-advertise&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Advertisers</a></dd>
</dl>
<dl>
  <dt class="firstChild">Services:</dt>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Faction%2FcdfProxy%3Faction%3Dsubscribe%26promo%3DONFLRNA4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Subscribe</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Faction%2FcdfProxy%3Faction%3Drenew%26promo%3DONFLRNA1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Renew</a></dd> 

  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Faction%2FcdfProxy%3Faction%3DpayBill%26promo%3DBNFLNBA1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800" rel="nofollow">Pay Bill</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Faction%2FcdfProxy%3Faction%3Dactivate%26promo%3DONFLNAA1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Activate Subscription</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fnejm-account&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800" rel="nofollow">Create or Manage Account</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fnejm-alerts&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Alerts</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Faction%2FshowPodcastsFeeds&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">RSS &amp; Podcasts</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Faction%2FcdfProxy%3Faction%3DauthorCenter&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800" rel="nofollow">Submit a Manuscript</a></dd>
  <dd class="lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Fmobile-applications&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800" rel="nofollow">Mobile</a></dd>
</dl>
<dl>
  <dt class="firstChild">Resources:</dt>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=http%3A%2F%2Fwww.nejmjobs.org%2F&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Physician Jobs</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Freprints&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800" rel="nofollow">Reprints</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Fpermissions&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800" rel="nofollow">Permissions</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fmedical-conference&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Medical Meetings</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Fupcoming-medical-conventions&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Conventions</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Ffrequently-asked-questions&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800" rel="nofollow">FAQs</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=http%3A%2F%2Fwww.jwatch.org%2F&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Journal Watch</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Fhelp&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800" rel="nofollow">Help</a></dd>
<dd class="lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fcontact-nejm&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800" rel="nofollow">Contact Us</a></dd>
</dl>
<dl>
  <dt class="firstChild">NEJM:</dt>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Fhistory-and-mission&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">About</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Fproducts-and-services&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Product Information</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Feditors-and-publishers&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800" rel="nofollow">Editors &amp; Publishers</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2F200th-anniversary-about&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800" rel="nofollow">200th Anniversary</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Fterms-of-use&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800" rel="nofollow">Terms of Use</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Fprivacy-policy&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800" rel="nofollow">Privacy Policy</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Fcopyright-information&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800" rel="nofollow">Copyright</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fabout-nejm%2Fadvertising-policy&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800" rel="nofollow">Advertising Policies</a></dd>
   <dd class="lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=http%3A%2F%2Fnejmgroup.org%2F&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">NEJM Group</a></dd>
</dl>
<dl>
  <dt class="firstChild">CME:</dt>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fcme%2Fweekly-cme-program&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Weekly CME Program</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fcontinuing-medical-education&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Browse Weekly Exams</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fcontinuing-medical-education%2Fcme-info&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Your CME Activity</a></dd>
  <dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Faction%2FcdfProxy%3Faction%3DcmeWeekly%26promo%3DONF4NA1V&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Purchase Exams</a></dd>
  <dd class="lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=%2Fpage%2Fcme%2Freview-cme&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Review CME Program</a></dd>
</dl>


<div class="socialNetworking">
  <div class="head">Follow us</div>
  <ul>
    <li class="firstChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=http%3A%2F%2Fwww.facebook.com%2FTheNewEnglandJournalofMedicine&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800" class="facebook"><img src="facebook.gif" alt="Facebook"></a></li>
    <li><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=http%3A%2F%2Ftwitter.com%2Fnejm&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800" class="twitter"><img src="twitter.gif" alt="Twitter"></a></li>
    <li><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=http%3A%2F%2Fwww.youtube.com%2Fnejmvideo&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800" class="youTube"><img src="youtube.gif" alt="YouTube"></a></li>
    <li class="lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3589&amp;url=http%3A%2F%2Fblogs.nejm.org%2Fnow%2F&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800" class="nowNejmBlog"><img src="nowatnejm.gif" alt="Now@NEJM Blog"></a></li>
  </ul>
</div>
    
    <!-- placeholder id=null, description=N-ad-footer-2 -->
        <div class="rightAd2"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=3261&amp;url=http%3A%2F%2Fwww.nejmgroup.org%2F&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800"><img src="NEJMgroup.gif"></a></div>
    
</div>










<div class="corners dropDown dropDown-myNejm">


	
<div class="wrap"><div class="topRow tl"><div class="tr"><div class="t">&nbsp;</div></div></div><div class="middleRow l"><div class="r"><div class="content"><dl class="column firstChild lastChild">
		<!-- placeholder id=null, description=N-menu-MyNEJM -->
	</dl></div></div></div><div class="bottomRow bl"><div class="br"><div class="b">&nbsp;</div></div></div></div></div>



<div class="corners dropDown dropDown-articles">



<div class="wrap"><div class="topRow tl"><div class="tr"><div class="t">&nbsp;</div></div></div><div class="middleRow l"><div class="r"><div class="content"><dl class="column more firstChild">
<dt class="firstChild">Article Category</dt>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/medical-articles/research">Research</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/medical-articles/review">Reviews</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/medical-articles/clinical-cases">Clinical Cases</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/medical-articles/perspective">Perspective</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/medical-articles/commentary">Commentary</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/medical-articles/other">Other</a></dd>
<dd class="moreLink lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/medical-article-index">Browse all articles</a></dd>
</dl><dl class="column multimedia more lastChild">
<dt class="firstChild">Multimedia</dt>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/multimedia/medical-videos">Videos in Clinical Medicine</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/multimedia/images-in-clinical-medicine">Images in Clinical Medicine</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/multimedia/interactive-medical-case">Interactive Medical Cases</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/multimedia/audio-summary">Weekly Audio Summaries</a></dd>
<dd class="moreLink lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/multimedia">Browse all multimedia</a></dd>
</dl></div></div></div><div class="bottomRow bl"><div class="br"><div class="b">&nbsp;</div></div></div></div></div>


<div class="corners dropDown dropDown-issueArchive">

<div class="wrap"><div class="topRow tl"><div class="tr"><div class="t">&nbsp;</div></div></div><div class="middleRow l"><div class="r"><div class="content"><dl class="column more firstChild lastChild">
<dd class="firstChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/toc/nejm/medical-journal">This Week</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/toc/nejm/lastweek">Last Week</a></dd>
<dd class="moreLink lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/medical-index">Browse full index</a></dd>
</dl></div></div></div><div class="bottomRow bl"><div class="br"><div class="b">&nbsp;</div></div></div></div></div>


<div class="corners dropDown dropDown-topics">






<div class="wrap"><div class="topRow tl"><div class="tr"><div class="t">&nbsp;</div></div></div><div class="middleRow l"><div class="r"><div class="content"><dl class="column more firstChild">
    <!-- placeholder id=null, description=N-menu-selectedSpecialties -->
        <dt class="firstChild">Selected Specialties</dt>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1367&amp;url=%2Fcardiology&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Cardiology</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1367&amp;url=%2Fendocrinology&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Endocrinology</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1367&amp;url=%2Fgastroenterology&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Gastroenterology</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1367&amp;url=%2Fgenetics&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Genetics</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1367&amp;url=%2Foncology-hematology&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Hematology/Oncology</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1367&amp;url=%2Finfectious-disease&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Infectious Disease</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1367&amp;url=%2Fnephrology&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Nephrology</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1367&amp;url=%2Fneurology-neurosurgery&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Neurology/Neurosurgery</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1367&amp;url=%2Fgynecology-obstetrics&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Obstetrics/Gynecology</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1367&amp;url=%2Fpediatrics&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Pediatrics</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1367&amp;url=%2Fclinical-practice-center&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Primary Care/Hospitalist</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1367&amp;url=%2Fpulmonary&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Pulmonary/Critical Care</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1367&amp;url=%2Fsurgery&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Surgery</a></dd>
<dd class="moreLink lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1367&amp;url=%2Fmedical-specialties&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Browse all Specialties &amp; Topics</a></dd>
    
</dl><dl class="column more lastChild">
    <!-- placeholder id=null, description=N-menu-featuredTopics -->
        <dt class="firstChild">Featured Topics</dt>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1366&amp;url=%2Fclinical-practice-center&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Clinical Practice Center</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1366&amp;url=%2Fhealth-policy-and-reform&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Health Policy and Reform</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1366&amp;url=%2Fmedicine-and-society&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Medicine and Society</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1366&amp;url=%2Fpage%2Fglobal-health&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Global Health</a></dd>
<dd class="lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/clickThrough?id=1366&amp;url=%2Fpage%2Finfluenza&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMra025195&amp;pubId=40057800">Influenza A (H7N9)</a></dd>
    
</dl></div></div></div><div class="bottomRow bl"><div class="br"><div class="b">&nbsp;</div></div></div></div></div>



<div class="corners dropDown dropDown-authors">

<div class="wrap"><div class="topRow tl"><div class="tr"><div class="t">&nbsp;</div></div></div><div class="middleRow l"><div class="r"><div class="content"><dl class="firstChild lastChild">
<dd class="firstChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/cdfProxy?action=authorCenter">Author Center</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/cdfProxy?action=authorCenter">Submit a Manuscript or Letter</a></dd>
<dd><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/cdfProxy?action=authorCenter">Track a Manuscript</a></dd>
<dd class="lastChild"><a href="http://www.nejm.org.libgate.library.nuigalway.ie/action/cdfProxy?action=authorCenter">Help</a></dd>
</dl></div></div></div><div class="bottomRow bl"><div class="br"><div class="b">&nbsp;</div></div></div></div></div>


























<script type="text/javascript">

/* <![CDATA[ */
var google_conversion_id = 1070139620;
var google_conversion_language = "en";
var google_conversion_format = "3";
var google_conversion_color = "666666";
var google_conversion_label = "_s1RCLTo-QEQ5JGk_gM";
var google_conversion_value = 0;
/* ]]> */
</script>
<script type="text/javascript" src="conversion.js">
</script><img src="untitled_001.dat" border="0" height="1" width="1">
<noscript>

<div style="display:inline;">
<img height="1" width="1" style="border-style:none;" alt="" src="http://www.googleadservices.com/pagead/conversion/1070139620/?value=0&amp;label=_s1RCLTo-QEQ5JGk_gM&amp;guid=ON&amp;script=0"/>
</div>
</noscript>







<div id="copyright">
    
    
            <p>Copyright © 2013 <a href="http://www.massmed.org/">Massachusetts Medical Society</a>. All rights reserved.</p>
        
</div>
<!--[if IE]></div><![endif]-->
<script language="javascript" src="searchbox_suggest_v1.js" type="text/javascript"></script>
<script language="javascript" type="text/javascript">

    try {
        __SLI_customisations[ __SLI_ApplicationName ][ 'ShowBrandingFooter' ] = false;
        sli_load();
    }
    catch (ex) {
        // If SLI scripts cannot be loaded, disable search hints
    }
</script>

<input id="showLayers" value="true" type="hidden">


    <!-- placeholder id=null, description=N-Layers_CONFIG -->
    <!-- placeholder id=null, description=N-ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=N-ad-promoLayer-1 -->
    
    
    

    <input id="IsInstitution" value="true" type="hidden">
    <input id="IsSubscriber" value="false" type="hidden">
    <input id="CustomerId" value="" type="hidden">
    <input id="firstAd" value="" type="hidden">
    <input id="secondAd" value="" type="hidden">




<script type="text/javascript">

        jQuery.extend(jQuery.mmsLayers.config, {
        rules: [{
                "name": "Launch Layer Ad",
                "frequency": 30,
                "showOnPage": 5,
                "enabled": false,
                "cookieName": "MarketingLaunchLayer",
                "styleClass": "launchLayer"
        },
        {
                "name": "Promo Layer Ad",
                "frequency": 42,
                "enabled": true,
                "cookieName": "PromoLayer",
                "styleClass": "promoLayer"
        },
        {
                "name": "Iperceptions - Ion Layer Ad",
                "showOnPage": 1,
                 "enabled": true,
               "test": false,
               "cookieName":"Iperceptions"
        }]
     });
    </script>

<script type="text/javascript">

    var _sf_async_config={uid:36099,domain:"nejm.org"};
    (function(){
        function loadChartbeat() {
            window._sf_endpt=(new Date()).getTime();
            var e = document.createElement('script');
            e.setAttribute('language', 'javascript');
            e.setAttribute('type', 'text/javascript');
            e.setAttribute('src',
                    (("https:" == document.location.protocol) ?
                            "https://a248.e.akamai.net/chartbeat.download.akamai.com/102508/" :
                            "http://static.chartbeat.com/") +
                            "js/chartbeat.js");
            document.body.appendChild(e);
        }
        var oldonload = window.onload;
        window.onload = (typeof window.onload != 'function') ?
                loadChartbeat : function() { oldonload(); loadChartbeat(); };
    })();

</script>

<!-- Load Footer JS via Ad Placeholders -->
<!-- placeholder id=null, description=N-config-js-global-bottom -->





        
<div style="position: absolute; display: none;" id="cluetip-waitimage"></div><div style="display: none; position: absolute;" id="cluetip"><div style="z-index: 1999; opacity: 0.1; top: 1px; left: 1px; position: absolute; background-color: rgb(0, 0, 0);"></div><div style="z-index: 1999; opacity: 0.1; top: 2px; left: 2px; position: absolute; background-color: rgb(0, 0, 0);"></div><div style="z-index: 1999; opacity: 0.1; top: 3px; left: 3px; position: absolute; background-color: rgb(0, 0, 0);"></div><div style="z-index: 1999; opacity: 0.1; top: 4px; left: 4px; position: absolute; background-color: rgb(0, 0, 0);"></div><div style="z-index: 1999; opacity: 0.1; top: 5px; left: 5px; position: absolute; background-color: rgb(0, 0, 0);"></div><div style="z-index: 1999; opacity: 0.1; top: 6px; left: 6px; position: absolute; background-color: rgb(0, 0, 0);"></div><div style="position: relative; z-index: 2000;" id="cluetip-outer"><h3 id="cluetip-title"></h3><div id="cluetip-inner"></div></div><div id="cluetip-extra"></div><div id="cluetip-arrows" class="cluetip-arrows"></div></div><div id="ui-datepicker-div" class="ui-datepicker ui-widget ui-widget-content ui-helper-clearfix ui-corner-all ui-helper-hidden-accessible"></div><script src="chartbeat.js" type="text/javascript" language="javascript"></script></body>
</html>
